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ABSTRACT
Protein-tyrosine kinases (PTKs) play essential roles in the cell signaling pathways
of eukaryotes. However, since their discovery, PTKs have also been linked to cancer
and it is now known that many of these enzymes actively promote oncogenic cell
signal transduction in unregulated forms. Therefore, there has been a concerted
effort on the part of researchers to identify the PTKs that potentiate such pathways,
characterize their regulatory properties, and develop strategies to selectively disrupt
these key elements of oncogenic signaling. Following this strategy, work described in
this dissertation first focuses on the characterization of a relatively unstudied PTK,
known as SRMS, which may be linked to cancer. To accomplish this, a novel strategy
was developed to purify active SRMS, which can also be used to purify other PTKs for
in vitro biochemical studies. Additionally, the purified SRMS was shown to activate
upon autophosphorylation of the activation loop tyrosine, representing the first
known regulatory mechanism of SRMS. The second focus of this dissertation was to
develop a novel strategy for the design of selective PTK inhibitors. Using dasatinib, an
established small-molecule inhibitor, a series of carboxyester-linked derivatives were
synthesized and evaluated against a panel of PTKs. The biochemical data obtained
presents a library of compounds with modified specificity toward individual PTKs.
Thus, this strategy represents a break-through in the development of new, more
selective PTK inhibitors for use as medicinal drug lead compounds.
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INTRODUCTION

Protein kinases and signal transduction
In the last century, scientific inquiry into the biochemical and molecular
mechanisms of carcinogenesis has led to many great advances in modern medicine’s
treatment of cancer and has profoundly enhanced our knowledge and understanding
of life at the cellular level. The application of the scientific method to tumor biology
was in its infancy at the beginning of the twentieth-century, a time when very little
was known about cancer’s causes and effective treatment strategies were not
available. However, in 1911, the Rous Sarcoma Virus (RSV) was discovered to induce
tumor formation in chickens by Peyton Rous.1 Combined with the elucidation of the
genetic code, Rous provided oncology researchers with a system to investigate the
basic components and genetic elements of signal transduction and cellular
transformation via kinases. Rous was recognized for this seminal achievement with
the 1968 Nobel Prize in medicine.

Kinases as oncogenes
In the middle of the last century, oncologists began questioning the infection,
or vector-driven, model of carcinogenesis and a new model began to emerge. It was
postulated that the onset and progression of cancer might be controlled through the
transformation of proto-oncogenes to oncogenes. Proto-oncogenes are genes that
have the capacity to promote cancer development through their encoded proteins
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and enzymes when they are activated by over-expression or mutation.2 The precise
mechanisms by which proto-oncogenes develop into oncogenes remains somewhat
controversial to this day, but almost certainly involves the accumulation of harmful
genetic mutations due to chance and environmental stressors.3 Following a decade of
research into oncogenes, the first oncogene was discovered within the RSV genome.
This oncogene was found to be v-src, a viral version of a normal cellular gene
of vertebrates, called c-src.4,5 This proto-oncogene is now known to be present in
virtually all metazoan organisms and plays an essential role in cell signaling. Soon
after its discovery, the protein product encoded by the src gene was found to belong
to a group of enzymes called protein kinases, capable of adding a phosphate group
onto the amino acid residues of cellular protein. Furthermore, Src represented a new
form of kinase, distinct in its ability to phosphorylate tyrosine side-chains of its
substrates, rather than serine or threonine.6
The isolation of the first oncogene was a long-awaited and significant
milestone in its own right. However, the origins and nature of this particular
oncogene, v-src, spawned an entire new field of research focused on understanding
the role of tyrosine phosphorylation in tumor progression and normal cell physiology.
The 1989 Nobel Prize in Medicine was awarded to Bishop and Varmus for their work
revealing v-src’s cellular origins. The discovery of protein-tyrosine kinases (PTKs) like
Src allowed Tony Hunter and numerous other pioneers in this new field, to discover
dozens of other oncogenes and proto-oncogenes.7 Today, many of the known
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oncogenes are kinases of some type and many others are directly influenced or
closely associated with kinase phosphorylation networks.

Functional significance of kinases
Approaching the turn of the century, the basic mechanisms governing
reversible protein phosphorylation by serine/threonine kinases (STKs) had also been
uncovered. Work that began in the 1950’s by Edmond Fischer and Edwin Krebs, who
won the 1992 Nobel Prize for their contributions, was joined by new STK and PTK
research that revealed the nature of protein kinases as major regulators of cellular
signaling by way of protein phosphorylation in eukaryotes. Upon completion of the
Human Genome Project, 473 human kinases had been discovered, largely through
sequencing analysis.8 Protein phosphorylation by these enzymes mediates signal
transduction and intracellular communication that controls cellular processes
including growth, development, division, replication, transcription, differentiation,
metabolism, apoptosis, homeostasis, motility, and structural rearrangements.9,10
Despite layers of redundancy and a system of fail-safes, disruption of these pathways
is known to occur, frequently driven by oncogenic kinases, which can result in cancer
and a host of other diseases.11
Due to their central role in governing both normal and pathological states,
protein kinases have long been considered primary targets for developing novel
therapeutic drugs, particularly PTKs like Src.2,11,12 Great advances have been made by
targeting some of the unique functional roles and structural features that distinguish
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PTKs from other off-target proteins and enzymes, leading to improved drug
specificity and reduced side-effects.13 Further advances in developing targeted
therapeutics will likely rely more heavily on an enhanced understanding of the
differences and commonalities that exist between individual protein kinases.
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Protein-tyrosine kinases (PTKs)
All protein kinases phosphorylate proteins on a select group of amino acid
side-chains: serine, threonine, or tyrosine. Each of these amino acids possesses a
hydroxyl group that serves as the basis for attachment of the γ-phosphate from ATP.
Although other amino acids are known to be modified by kinases, serine, threonine,
and tyrosine phosphorylation are by far the most common and best understood.14
Phosphorylation is a post-translational modification, meaning that it occurs
after the protein has been made. As with many other post-translational
modifications, phosphorylation is a structural modification that often elicits a
conformational change within the protein. In many instances, dramatic protein
folding rearrangements can occur in a protein substrate, precipitating major
functional and regulatory changes. In the classic example of glycogen phosphorylase,
phosphorylation results in substantial rearrangements which lead to the activation of
the enzyme.15 However, phosphorylation can also have an inhibitory effect on certain
enzymes like isocitrate dehydrogenase and Src.16,17 Other enzymes, such as the
protein-tyrosine kinase Src, can be regulated by more than one phosphorylation
event to enable modulation of enzymatic activity via several distinct conformations.18
Importantly, protein phosphorylation is chemically reversible, but stable
enough under normal physiological conditions to ensure lasting signal fidelity. To
turn this signal “off”, cells employ another set of enzymes called phosphatases, which
have phosphoprotein-specific catalytic ability to dephosphorylate select amino acids.
There are three distinct groups of enzymes that have evolved to counter protein
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kinase activity in this manner. Phosphatases like PP1, belonging to the protein
phosphatase Mg2+ / Mn2+ -dependent (PPM) family, and PP2C, of the phosphoprotein
phosphatase (PPP) family, are specific to serine/threonine dephosphorylation.
However, the independently evolved protein-tyrosine phosphatase (PTP) family of
enzymes (e.g. PTP1B) is responsible for the vast majority of phosphatase activity
toward phosphotyrosine-containing proteins and peptides.19
In addition to the structure-function effects upon the substrate,
phosphorylation often serves as a “tag” that can be recognized, or bound, to recruit
other proteins, enzymes, and substrates of the kinase signaling pathway. To this end,
many proteins and enzymes, including kinases, have evolved discrete domains that
specialize in recognition of phosphorylated stretches of peptide sequence. For
example, the Src Homology 2 (SH2), 14-3-3, and phosphotyrosine-binding (PTB)
domains are crucial components of signaling, for their specificity toward tyrosinephosphorylated peptides.20 The ability of these domains to facilitate interaction with
phosphopeptides has enabled kinases and phosphatases to develop the highly
elaborate cell signaling networks that are necessary for eukaryotic organisms.10,21
Eukaryotic protein kinases can be broadly grouped into two categories, STKs
and PTKs, based upon their substrate preferences. Protein-tyrosine kinases differ in
that they strictly phosphorylate specific tyrosine residues, not serine or threonine.
Combined with the phosphotyrosine-specific binding domains and protein-tyrosine
phosphatases, PTKs have evolved independently from STKs to delicately balance the
kinase signaling networks of all metazoan life.22,23
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Defining characteristics of PTKs
PTKs diverged from STKs over half a billion years ago, just prior to the
evolution of multicellularity in the metazoan lineage.24 PTKs represent one of about
eight uniquely metazoan families of enzymes and likely played a key role in the
evolution of multicellularity by providing cells with a new signaling mechanism that
would be less disruptive to the essential STK pathways, already present.23 The
protein substrates of PTKs are frequently targets for modification by STKs and other
signaling

enzymes,

too.

In

this

manner,

serine/threonine

and

tyrosine

phosphorylation networks, collectively known as the kinome, are an integral
component of a vast network of cell signaling.
While there are no clear-cut roles or pathways that can be used to
categorically distinguish the PKs from one another, there are some generalizations
that can be made from the perceived influence or importance of either on certain
cellular functions. STKs, like the cyclin-dependent kinases, are often thought of as the
central regulators of the cell cycle, while PTKs generally appear to exert the most
control over the development and differentiation of cells in response to stimuli,
exemplified by the numerous growth factor receptor kinases. PTKs account for less
than 1% of the total protein phosphorylation of the cell, despite having generally
higher enzymatic turnover. Thus, PTKs appear to be much more tightly regulated,
compared to STKs.
It has been proposed that the aromatic component of phosphotyrosine may
have provided a better target for the evolution of the large number of

7

phosphospecific intermolecular interactions that are necessary for evolving a tightly
regulated signal transduction pathway, largely mediated by SH2 domains and
protein-tyrosine phosphatases (PTPs). Together, PTKs, PTPs, and SH2 domains
function in concert using a ‘write-read-erase’ system that is both rapid and dynamic.
Through this context, one can begin to understand the unique nature of PTKs as
dynamic regulators of cell signaling and as obvious targets of investigation for basic
and clinical research.8,9,13
Structural and biochemical studies of the kinase domains of these two groups
support the separate classification of STKs and PTKs.8,25 The catalytic loop regions of
STKs frequently possess a lysine residue, such as the catalytic loop YRDLKPEN
sequence found in PKA. However, PTKs share an sequence containing arginine (e.g.
HRDLAARN in IRK, and numerous others) that is highly conserved. This catalytic loop,
in conjunction with several other residues of the kinase catalytic domain, is largely
responsible for the differences in amino acid preference observed between STKs and
PTKs.26 Yet, comparisons also reveal a significant level of conservation concerning the
folding of the kinase domain and the molecular basis of PK catalysis within the active
site.

Structure and domain architecture of PTKs
While STKs and PTKs share a great deal of homology, the relative conservation
of regulatory domains/features of PTKs and the distinct pathways in which they
operate suggest that PTKs merit investigation as a distinct family of enzymes,
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independent from STKs. PTK catalytic domains are found to exist in about a hundred
different human proteins. There are two main classes of protein-tyrosine kinases:
receptor (trans-membrane) and non-receptor (cytosolic).
Receptor PTKs (RTKs) possess extracellular and trans-membrane domains, at
the N-terminus, and at least one catalytic domain that resides within the cytoplasm,
but in close proximity to the membrane. Currently identified, there are
approximately 20 distinct families of RTKs. There are several RTKs that are prominent
figures in cell signaling, including members of the fibroblast, epidermal, vascular
endothelial, and insulin-like growth factor receptor (FGFR, EGFR, VEGFR, and IGFR)
families. RTKs are responsible for the recognition and initiation of many different
types of signaling molecules. Both large and small proteins, as well as several small
molecules of native and foreign origins have been found to bind the extracellular
domains of RTKs to initiate signaling cascades. Frequently, binding of the extracellular
RTK substrate induces dimerization of the receptor which, in turn, promotes
activation of the kinase by way of trans-phosphorylation. The active kinase will then
proceed to phosphorylate one or more downstream proteins and enzymes, often
amplifying the signal.
Many times, the RTKs will activate other PTKs, including non-receptor PTKs
(nrPTKs) which do not exclusively associate with the cell membrane. The nrPTKs are
often referred to as cytosolic, but this label fails to convey the dynamic localization
patterns of these important enzymes. In fact, nrPTKs are frequently found in transit
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between various cellular locations and organelles, such as the plasma membrane and
the nucleus.
The domain architecture of nrPTKs is fairly variable, but most contain at least
one Src homology 2 (SH2) domain to facilitate interaction with RTKs and other
phosphorylated proteins. SH2 domains contain approximately 100 amino acids and
bind to phosphorylated tyrosine containing peptides. SH2 domains are frequently
responsible for localization to RTKs and other enzymes that have been activated by
tyrosine phosphorylation. Aside from this prototypical function, SH2 domains also
can play critical roles in the catalytic regulation of the enzymes to which they are
tethered. Frequently, the SH2 domains of kinases are found just upstream of the
catalytic domain.
Another prototypical nrPTKs domain is the Src homology (SH3) domain, which
specializes in recognition of proline-rich peptide sequences. SH3 domains are roughly
60 amino acids long. Like SH2 domains, they can contribute greatly to localization
and regulation of kinases or other SH3 domain containing proteins. In nrPTKs, the
SH3 domain is positioned near the N-terminus, just before the SH2 domain. This SH3SH2-kinase domain architecture is a common feature to the majority of nrPTKs and is
exemplified by the Src, Abelson murine leukemia viral oncogene homolog 1 (Abl), Cterminal Src Kinase (Csk), Fyn related kinase (FRK), and Tec families of proteintyrosine kinases.
In addition to the aforementioned SH3 and SH2 domains, over two dozen
different types of accessory protein sequences and domains can be found alongside
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PTK catalytic domains, at either the N- or C-terminal regions of the kinases. Many of
these domains are found to contribute to the regulation of the kinase domain, by
way of intramolecular and intermolecular interactions. Such interactions modulate
the kinase activity by stabilizing or destabilizing the active and inactive conformations
of the catalytic domain. Furthermore, accessory protein domains frequently
determine or influence sub-cellular localization and recruitment of PTK substrates
through direct and indirect molecular complexes.
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Figure 1. The Conserved SH3-SH2-Kinase Domain Architecture of nrPTKs
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Figure 2. Non-receptor protein-tyrosine kinases
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Model kinases of interest
The large number and diversity of PTKs, including non-receptor PTKs, presents
a daunting challenge to researchers attempting to understand the signaling dynamics
of cells. In order to narrow the focus of research, PTKs have been subdivided and
grouped according to their structural similarities. Besides possessing a high degree of
sequence homology, there is a clear pattern of conservation regarding accessory
domains and other known regulatory features within each of these families. The
observed characteristics of a single, model kinase can be used to infer similar
functionality to other related enzymes that share the necessary structural
components.
In this manner, implicit models can be created to help piece together a view
of the larger signaling dynamic of the cell and provide the insight necessary for future
investigation and further refinement of our understanding. The Src, Abl, Csk, FRK,
and Tec enzymes often serve as model kinases, representing their respective family
member nrPTKs. Studying the structural and functional differences between these
kinases has proven to be instrumental in understanding how nrPTKs help to govern
cell signaling.
Src was the first PTK discovered and, therefore, rapidly became one of the
best studied enzymes. Src and other Src family kinases (SFKs) are best known as
major components to many growth factor signaling pathways, often directly
interacting with growth factor receptors. Through various receptors, SFKs help to
regulate growth, differentiation, migration, survival, and numerous other processes
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in tissues throughout the body. Abnormally elevated SFK activity levels are closely
associated with oncogenesis in humans, particularly in certain types of colon cancers,
melanoma, leukemia, and lymphoma.
Similarly, Abl family kinases (AFKs) are best known for their potential to cause
cancer. Philadelphia chromosome positive ALL and CML is a direct result of oncogenic
Abl. However, like Src and other proto-oncogenic PTKs, Abl also contributes to
normal cell signaling pathways such as growth, survival, and the DNA-damage
response.27 Abl family kinases are most notably distinct from SFKs due to their Nterminal Tec homology (TH) domain and Pleckstrin homology (PH) domain and large
C-terminal region which contain numerous accessory domains governing kinase
localization and function. Within the C-terminal region, Abl contains three nuclear
localization signals and a nuclear export signal, which is suggestive of the tight, highly
dynamic regulation of this PTK.27
Aside from their roles in malignancy, PTKs can also play major parts in tumor
suppression. Csk and its relatives are known tumor suppressors. These PTKs
phosphorylate other kinases, particularly the SFKs, rendering them inactive. In fact,
the Csk family of enzymes appears to have evolved almost exclusively to negatively
regulate SFKs, keeping their signals in check and preventing oncogenic signaling.
Inactivation of SFKs by Csk is perhaps the best understood mechanism of nrPTK
regulation. Study of this interaction has greatly enhanced understanding of PTK
substrate specificity.
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After the SFKs, the Tec family of kinases (TFKs) is the largest group of nrPTKs.
Expressed primarily in hematopoietic cells, such as T cells, TFKs play vital roles in the
signaling of the immune response and lymphocyte development. This kinase family
appears uniquely regulated and contains various N-terminal domains such as prolinerich regions, TH domain, and/or PH domains. Operating downstream of antigen
receptors, Tec family kinases often become activated through SFK-mediated tyrosine
phosphorylation.28 Aside from normal cellular function, the role of these kinases in
human disease is much less clear at this time.
The last of the nrPTK groupings is the FRK family kinases (FFKs). Little is known
about these kinases, which have only recently been revealed to be distinct from SFKs.
While there does appear to be some overlapping substrate specificity with SFKs,
several novel interactions have also been reported. Importantly, FFKs appear to
possess the capacity to operate as both tumor suppressors and oncogenes,
depending on the cellular context.29 However, the mechanisms by which FFKs
maintain such a dynamic is currently unknown. The FFKs are discussed in further
detail later in this review.
PTKs share a common mechanism of catalysis, yet each of these nrPTK
families has evolved to perform unique functions within the cellular environment.
Many kinases are co-expressed within a given cell and yet each achieves very
different patterns of phosphorylation. This can only be possible if the regulation of
their enzymatic capabilities is finely tuned to suit the evolved genetic program. How
each of these related kinase families co-evolved to maintain such a dynamic is not
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completely understood. Therefore, much research has focused on identifying the
unknown features that are responsible for each kinase’s unique activity profile.
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PTK enzyme catalysis
In order to understand the differences between PTKs, it is essential to identify
commonalities that may exist. Structural and biochemical studies of many kinases
have revealed a great deal about the essential catalytic ability of these enzymes. By
comparing the relative catalytic abilities and structural differences between kinase
families, several key components of PTK regulation are now well understood.
PTK catalytic domains consist of two distinct lobes, hinged together to form
the catalytic cleft.30 Most of the N-terminal residues of the catalytic domain form the
ATP-binding lobe, while many of the C-terminal residues are contained within the
lobe commonly referred to as the substrate binding lobe.30 Each of these subdomains is a misnomer, however, since both domains play crucial roles in binding
ATP and other substrates of the kinase. In the active conformation(s), the PTK must
simultaneously bind both of its substrates, peptide and ATP, within the active site.31
As ATP and the tyrosine containing peptide each bind, ATP hydrolysis and
transfer of the γ-phosphate occur independent of an intermediate step. Catalysis is
greatly enhanced in the presence of normal physiological concentrations of several
divalent metal cations, frequently Mn2+ or Mg2+, which can bind dynamically to the
catalytic cleft of the enzyme.32 While PTKs accomplish substrate phosphorylation
with a wide range of efficiency, their catalytic mechanisms are virtually identical. This
is reflected quite clearly by the high degree of conservation observed within multiple
sequence alignments of the PTK catalytic domains (Figure 3), particularly within the
active site.
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The specific amino acids that surround the tyrosine residue of the substrate
are known to have dramatic effects on overall catalytic efficiency. However, there is
no clear pattern of preference that is shared between all PTKs, with regard to the
specific sequence of amino acids adjacent to the target tyrosine of known substrates.
This means that a small tyrosine containing peptide that is a great substrate for one
PTK will not necessarily be phosphorylated by a different PTK, even if both enzymes
are determined to be equally active toward a common substrate. For example, Src
and Csk are both able to phosphorylate the generic substrate PolyE4Y quite well, yet
Csk is unable to phosphorylate known Src substrates such as Cortactin. Likewise, Src
shows no significant activity toward its own C-terminal tail tyrosine, a known
substrate for Csk.33
In addition to the variability of efficiency stemming from local sequence
preferences, enhanced catalytic efficiency can also be achieved through more distally
located interactions. In such cases, the local sequence appears to play only a minor or
secondary role as other, more remote docking sites facilitate interaction, or substrate
recognition. One such case is the docking interaction of Src to Csk. In order for Csk to
phosphorylate the C-terminal tail tyrosine, to inactivate the enzyme, a stretch of
amino acids from Csk’s substrate binding lobe, RSRGRS, is an essential part of the
recognition of Src. This region, well outside the catalytic cleft, is necessary to achieve
phosphorylation and inactivation of Src via Csk.33
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Figure 3. Sequence alignment of selected model nrPTKs.
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SRMS
As more is uncovered about each kinase, our model of the elaborate network of
PTK signaling within the cell is improved. When researchers began focusing more
closely upon the distinct members of the Src family kinases, it became apparent that
several of these kinases were relative outliers in terms of their genetic, structural,
and functional differences. These outliers were re-classified into a new family of
nrPTKs and the true nature of these enzymes continues to be a focus of research, at
present. The human members of the FRK family of non-receptor PTKs (FFKs) initially
appeared to share identical accessory domain architecture with SFKs. However,
closer inspection has revealed many elements that are crucial to the functional
regulation of SFKs appear to be absent or markedly distinct within the FFKs.

FRK family kinases
FRK, also known as RAK, has been found in human liver, kidney, mammary,
and epithelial tissues and appears to play roles in cell growth, differentiation,
apoptosis, and proliferation.29 Like all FFKs, FRK does not appear to localize to the cell
membrane in the same manner as SFKs, due to a lack of a functional N-terminal
myristoylation domain. However, FRK does contain a functional nuclear localization
signal within its SH2 domain.34 The enzymatic regulation of FRK is thought to
resemble that of SFKs, due to the presence of conserved tyrosine residues within
both the activation loop and C-terminal tail regions.
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Found on chromosome 6 q21-22.3, FRK is reported to be amplified in several
colon cancers34 and many mammary tumors35, suggesting its potential as an
oncogene. In contrast, this region is also frequently deleted in several breast
cancers36 and appears to activate PTEN, a known tumor suppressor.29 PTEN has been
found to be a direct substrate of FRK, and phosphorylation of PTEN by FRK prevents
PTEN degradation.37 PTEN, in turn, inhibits the function of AKT, and therefore, the
phosphoinositol-3-kinase/AKT growth, proliferation, survival, and metabolism
pathways.
Brk is also known to play an inhibitory role in this pathway, through direct
interaction with AKT.38 Brk, sometimes also referred to as PTK6 or PTK70, is the
second member of the loosely-related FFKs. Brk shares 44% amino acid identity with
FRK.29 For comparison, Src and Abl share 41% identity, despite being grouped into
different families.27 Brk also appears to share the components necessary for Src-like
regulation. Brk is located on chromosome 20 q13.3-13.4 of humans and has been
implicated in apoptosis, differentiation, and cell migration.29 Primarily expressed in
differentiating intestine and skin cells, Brk is also amplified in several breast cancers,
with and without the neighboring HER2 oncogene.39
Thus, like FRK, Brk has been found to both promote and suppress the
oncogenic potential of specific tissues. Together, this suggests that the FRK family
kinases are dynamically regulated in a tissue and context-specific manner. FRK and
Brk appear to share some functional overlap with each other, as demonstrated by
their common influence on the AKT signaling pathway. However, a great deal is still
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unknown of these two FFK members. SRMS is the last human PTK member of the FRK
family, and even less is known of this enzyme.
SRMS is located approximately 1 kb downstream from Brk, likely arising from
an ancient duplication event. Additionally, the exon structure of all three human FFKs
is nearly identical. Despite these similarities, the primary structure of SRMS appears
to be quite dissimilar in several important ways. Specifically, sequence analysis
indicates that SRMS lacks a C-terminal tail tyrosine and it is unclear whether its SH3
domain is functional. Beyond some limited expression data and brief mentions within
the context of other studies, very little is known about SRMS.

Significance of SRMS
Within the understudied FRK family of nrPTKs, SRMS is the least well
characterized. This enzyme was discovered from various tissues of mice in 1994, and
has since been found to be expressed in rats and humans, as well.8,40 Beyond its
discovery, no published data currently exists to describe the purification, potential
function, or regulation of this enzyme. However, metadata available from highthroughput assays of normal and experimental tissue samples supports the
ubiquitous pattern of expression described in these early reports.
The wild-type catalytic domain of SRMS has been purified from insect cells
and is commercially available through several companies. Several reports have
utilized such sources of SRMS, but due to low intrinsic activity toward the chosen
substrates, it is unclear whether this form of SRMS is suitable for in depth studies.
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Without any viable means of generating the necessary constructs for full in vitro
biochemical study, SRMS has gone virtually unstudied. Yet, each of its most closely
related kinases have been implicated in major signaling pathways of cancer cells and
tissues. Additionally, SRMS offers a unique chance to study regulatory mechanisms of
kinases because it does not appear to contain the key regulatory structural features
found in many model kinases.
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Regulation of PTKs
Although the primary function of PTKs is to propagate cellular signals via
tyrosine phosphorylation, these enzymes are often substrates, themselves, of
upstream PTKs. Many tyrosine kinases are known to be regulated by numerous posttranslational modifications, particularly via tyrosine phosphorylation. In fact,
phosphorylation by other kinases and dephosphorylation by phosphatases appears to
be a primary regulatory mechanism of PTK activity. In some cases, patterns of
phosphorylation appear to have a greater impact on overall kinase activity than even
large-scale changes in expression could produce. Thus, there are a few conserved
mechanisms of PTK regulation by phosphorylation that must be considered.

Activation of PTKs by autophosphorylation
Most PTKs contain a flexible peptide loop region within the substrate binding
lobe that harbors a tyrosine residue. This amino acid, upon phosphorylation, often
activates the kinase by stabilizing the active conformation. Therefore, this region of
the catalytic domain has come to be known as the activation loop. Many kinases
possess the ability to phosphorylate this position in trans fashion, and is referred to
as autophosphorylation. Many PTKs that are regulated by autophosphorylation,
including the Src family kinases, have been shown to be activated many fold
following phosphorylation, with profound cellular consequences.
Besides

Src

and

its

closest

relatives,

Abl

is

also

capable

of

autophosphorylation within the activation loop, leading to activation in vitro.41 Thus,
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phosphorylation of the activation loop serves as an important molecular marker of
potential PTK activity for both Src and Abl. Some kinases are unable to
autophosphorylate their activation loop tyrosine. For example, activation loop
phosphorylation increases Tec family kinase activity. However, these kinases do not
appear to self-phosphorylate.28 Other PTKs like Csk contain no activation loop
tyrosine residue at all. Thus, the role that activation loop phosphorylation or
autophosphorylation has in PTK regulation appears to be a major mechanism of
regulation that has been differentially conserved by non-receptor PTKs.

Inactivation of PTKs
Phosphorylation is also known to inactivate kinases. In the classic example,
the Src family kinases may be phosphorylated at an alternative regulatory position on
a short, conserved peptide “tail” that contains a tyrosine residue, just following the
C-terminal portion of the catalytic domain. This C-terminal tail is exclusively
phosphorylated by Csk.17 Upon phosphorylation of the tail tyrosine by Csk, Src
undergoes a dramatic conformational rearrangement, leading to an inhibited
conformation. In crystal structures of this inactive form of the kinase, the SH2
domain of Src is bound to the C-terminal tail phosphotyrosine in what is known as
the “tail-bite” conformation.30
The phosphorylation of the activation loop and C-terminal tail are two
opposing mechanisms and are perhaps the two best understood modes of nrPTK
regulation. Although many PTKs possess an activation loop tyrosine, and therefore
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the capacity to be regulated by autophosphorylation, relatively few mechanisms of
inactivation have been confirmed for PTKs beyond the Src family tail-bite
conformation. However, C-terminal tail phosphorylation may not be required for
some kinases to achieve similar inhibited forms.
In the case of Abl, found in PDB entry 1OPK, the auto-inhibited enzyme
reveals a conformation that is surprisingly similar to Src’s tail-bite form.42 Even
though Abl lacks a C-terminal tail tyrosine, the myristoylation domain of its Nterminus appears to facilitate the necessary interactions between the SH2 and
catalytic domains to inhibit the enzyme.27 Additional modes of negative regulation
have been proposed for other families of nrPTKs that lack a conserved C-terminal
tyrosine, as well.
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Figure 4. Regulation of Src Family Kinases
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In vitro characterization of kinases
Much of what is known today of the function and regulation of kinases has been
pieced together from the careful analysis of in vitro biochemical data. Purifying
proteins and enzymes from in vivo tissue samples is frequently possible, but this
approach is often quite limiting to researchers. Yields obtained from living or cultured
sources are typically low and mutational analysis is difficult. Therefore, recombinant
protein expression systems are often favored for obtaining and purifying sufficient
amounts of active enzyme for use in biochemical assays. However, purification of
active kinases from recombinant expression and purification strategies has proven
relatively difficult, historically.

Systems of expression and purification
PTKs are most commonly expressed within two different hosts for high yield
production of active, recombinant enzyme: insect cells and E. coli. Insect cells
generally are able to produce the highest yields, yet growth time and cost are two
major downsides for many studies. This system is expensive and particularly difficult
to rapidly generate many different constructs of a single enzyme for mutational
analysis. E. coli, however, is both rapid and inexpensive.43 Moreover, numerous
advancements have been made toward improving the overall yield of enzyme
produced from bacterial expression, through optimization of growth media.44 Thus,
heterologous expression of kinases within E. coli is generally a preferred means of
producing active enzyme for in vitro characterization.45 Despite the numerous
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advantages offered from recombinant expression systems, there are several
potential pitfalls that may prevent the purification of active kinase from these
systems.

Major obstacles to expression and purification of PTKs from E. coli
Prokaryotes, such as E. coli, have not evolved to tolerate high levels of
tyrosine phosphorylation. Therefore, high level expression of kinases frequently
becomes toxic to the bacteria and greatly diminishes overall yield and/or reliability of
the enzyme obtained. In such cases, several strategies have been employed to
successfully counteract the toxicity of recombinant PTK expression: reducing “leaky”
expression and co-expression alongside a recombinant protein-tyrosine phosphatase
(PTP). Many strategies exist to reduce leaky expression and improve inducible
promoter control,46 but many appear insufficient for recombinant expression of
select PTKs. However, co-expression of PTKs alongside PTPs, such as PTP1b, has
alleviated toxicity of PTKs in a number of bacterial systems.45,47,48 Phosphatase coexpression systems have been successfully employed to produce important Src and
Tec family kinases, as well as several receptor PTKs of clinical interest.
Besides toxicity concerns, proper protein folding and solubility are also
particularly difficult to achieve with some PTKs expressed in bacterial systems.
Solving such problems in expression and purification is perhaps the largest, most
difficult task for kinase researchers, currently. Frequently, PTK folding and solubility
can be improved by expressing these enzymes as fusion proteins to common affinity
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chromatography tags, such as glutathione S-transferase (GST) and maltose binding
protein (MBP).49 Also, due to the relatively rare use of certain codons within
prokaryotes, codon optimization and/or co-expression of genes that elevate levels of
specific amino-acyl tRNAs have also proven quite effective to improve solubility of
heterologous proteins.50 Several E. coli strains have been developed to circumvent
rare codon usage and these commercially available expression hosts have proven
quite successful.
Despite affinity tag and codon usage optimization, many PTKs remain difficult
to purify in sufficient quantities due to improper folding and/or poor solubility. To
address this issue, several E. coli expression systems have been supplemented with
additional genes to produce various chaperone proteins. These proteins serve to
guide protein folding and re-folding and are frequently used for expression of PTKs
and many non-PTK enzymes, as well.51,52 The GroES and GroEL proteins that make up
the GroESL chaperone complex are among the most frequently used in the
recombinant expression of PTKs.
GroEL is a member of the Hsp60 family of protein chaperones, found in
eukaryotic mitochondria and prokaryotes such as E. coli.51 GroEL may independently
aid in the folding and solubility of proteins, but commonly associates with the much
smaller GroES. GroEL associates independently into a grand molecular cylinder,
consisting of two heptameric GroEL rings. Seven GroES members also self-assemble
to form molecular “caps” to the GroEL cylinder, trapping the improperly folded
protein within, and ATP hydrolysis serves to power protein re-folding by the
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macromolecular assembly.53 A major drawback to GroESL overexpression systems is
the tendency of GroEL to co-elute with recombinant protein of interest, requiring
further purification steps.48,54 Despite this potential complication, GroESL and other
chaperones have proven quite successful in obtaining soluble, active kinases.
Each of these strategies to alleviate toxicity and improve solubility and folding
of PTKs in recombinant expression systems has proven successful in producing high
yields of active kinase. Often, several or all of the discussed strategies are employed
to achieve adequate expression and purification of nrPTKs. Despite all the PTKs
purified successfully, no universal expression system currently exists. Since
researching the biochemical nature of a given kinase is frequently plagued by one or
more of these issues, there remains great interest in optimizing existing strategies
and developing new methods for the expression and purification of PTKs.
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PTKs as therapeutic drug targets
Inactivation of kinases is an important objective for the treatment of many
diseases. Under-regulated or overly stimulated kinase activity can lead to disastrous
consequences for the affected cell, tissue, and the entire body. In the case of many
cancers, in particular, such kinases cause or drive the cell changes necessary for
proliferation and metastasis. Therefore, for over two decades, a great deal of interest
has been paid to the development of safe, effective kinase inhibitors for the
treatment of various afflictions. However, often times it is unclear which kinases to
target to achieve effective therapeutic strategies.
In addition to those previously discovered kinases, the completion of the
human genome project allowed for the identification and classification of all PTKs
within the human kinome. Through analysis of the structure and expression, these
PTKs have been grouped and labeled as members of various families. However, it
may be important to note that such distinctions are frequently made without the
proper empirical data to conclusively differentiate the cellular function and/or
regulation of separate PTK families. Thus, identifying the PTKs that directly influence
a given pathology can become quite difficult, and the literature is full of evidence
that is seemingly contradictory, greatly confounding the efforts to choose an
appropriate PTK target for design of novel therapeutics.
Another hurdle to the development of kinase inhibitors has been generating
proper specificity toward the errant kinase, or kinases, in order to refrain from
damaging normal processes of the target tissues. Within the last ten years, major
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breakthroughs have enabled the therapeutic targeting of PTKs and, in some cases,
eliminated the need for highly toxic and non-specific radiation and chemotherapeutic
treatments. By harnessing the power of small molecule PTK inhibitors, anticancer
treatments have made significant progress in targeting PTKs that drive cancer.

Small molecule PTK inhibitors
In some acute lymphoblastic and chronic myeloid leukemia patients, a specific
genetic defect called the Philadelphia chromosome (Ph+) results in the expression of
an unregulated form of the PTK, Abl. This errant kinase is actually a fusion protein
which consists of a truncated form of the BCR protein that replaces portions of the Nterminal regulatory domain of the Abl kinase (BCR-Abl). Without this region,
autoinhibition of Abl is greatly impaired, leading to the reprogramming of the cell
signaling network and, ultimately, leukemia. Thus, BCR-Abl represents one of the
best, clear-cut examples of a PTK drug target.
In 2004, Bristol-Myers Squibb announced the discovery of Gleevec, or
imatinib, as the first small molecule compound to effectively target BCR-Abl and treat
Ph+ patients. Prior to the introduction of imatinib, Ph+ patients suffered intolerable
treatment regiments and incredibly high mortality rates. Imatinib and several other
drugs with similar mechanisms of action have now been approved for various
pathologies, greatly enhancing patient outcomes through targeted disruption of
PTKs. Guided by the successes of imatinib, the investigation of new and improved
PTK inhibitors has been and continues to be of great interest.
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Generating PTK specificity
The structure of imatinib and the other small molecule PTK inhibitors are
often quite dissimilar, yet each inhibits BCR-Abl by binding to the ATP-binding cleft of
the kinase. This high affinity interaction disrupts the recruitment of substrate and/or
reduces catalytic activity. The precise region of the catalytic cleft that each inhibitor
may occupy is somewhat variable, from compound to compound. However, within
this small cleft, there are a limited number of residues and/or motifs that may
significantly contribute toward generating the type of high affinity interaction that a
PTK inhibitor requires. Because of this, a simple mutation in BCR-Abl can result in
resistance to multiple inhibitors.12
Additionally, since the active sites of many kinases are generally well
conserved, it is often difficult to generate novel compounds that exclusively disrupt
the target kinase. For example, while imatinib can inhibit Abl at sub-micromolar
concentrations, it has also been demonstrated that similar concentrations can
disrupt off-target kinases, such as KIT, Lck, and PDGFR.55,56 Later generation drugs
targeting BCR-Abl, such as dasatinib (Sprycel) and nilotinib (Tasigna), also inhibit
several known off-target kinases. In addition to these kinases, it has been proposed
that any of the over 2,000 other nucleotide-dependent enzymes that are found in
humans could be potential targets, due to similarities they share with the active sites
of PTKs.12 Through examination of primary sequence alignments that compare
various nrPTKs, it is clear that those regions responsible for interacting with most of
the approved and investigational drugs are among the better conserved portions of

35

kinases. However, there are other regions that show great variation and may provide
better targets for new drugs aimed to improve the specificity of PTK inhibition.

Drug resistance and toxicity
It is widely believed that most patients undergoing treatment with kinase
inhibitors will eventually develop resistance. Drug resistance arises from several
possible events that commonly occur during the progression of tumorgenesis,
because cancerous cells are frequently in a state of constant genetic flux. Deletions,
amplifications, translocations, and mutations are not only causes of cancer, but also
drivers of its progression and a means to acquire drug resistance. Many mutations
have been found in cancer cells that disrupt inhibitor binding. Because of this, second
generation kinase inhibitors have been developed, such as dasatinib, which are able
to bind despite many of these common mutations.57
However, even dasatinib, one of the best second generation drugs, fails
eventually due to the accumulation of certain additional mutations. For example, the
mutation of amino acids at positions homologous to a threonine in Abl (T315I), KIT
(T670I), and EGFR (T790M), all confer clinical resistance to imatinib. This residue
(known as the gatekeeper) is one of a handful of mutations that can destroy the
effectiveness of dasatinib and all other second-generation kinase inhibitors as well.56
Examination of the crystal structures of kinases, in complex with these
compounds, reveals that the gatekeeper residue resides in the ATP-binding cleft of
the kinases and forms a hydrogen bond with each of the inhibitors. Without the
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gatekeeper-inhibitor interaction, these mutant kinases are much less energetically
suited to bind the therapeutic compounds and often require concentrations of
several orders of magnitude greater to achieve inhibition. Often, these dosages prove
to be toxic to patients and would result in significant side effects or even death.
The problem of toxicity may seem to exacerbate the issues of resistance;
however, it is important to note that toxicity can contribute to the development of
drug resistance, in the first place. Imatinib was originally reported as an inhibitor of
the Abl kinase domain, but has since been confirmed to target numerous other
kinases at clinical, and even subclinical, concentrations. No kinase inhibitor has been
experimentally shown to target a single, clinically relevant kinase without
simultaneously inhibiting other “off-target” kinases. While kinase inhibitors have
undoubtedly proven to be a major advancement in the specificity of chemotherapy,
clinical doses must still be tempered to alleviate the toxic side effects that are
caused, in part, by the inhibitors’ lack of specificity. With such lower doses, there is a
greater risk of the cancer progressing and developing resistance before complete
eradication of the diseased tissues’ cells.12 Therefore, there is currently great interest
in the development of novel compounds with enhanced specificity toward PTKs to
help alleviate the major problems of toxicity and resistance.
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Focus of this thesis
The experimental data, results, and discussion of work derived from this
thesis focuses on two distinct projects, yet each are aimed at identifying specific
elements of PTKs that may serve to regulate the enzymatic activity of these highly
important and influential enzymes. The first of these projects centers on the hitherto
understudied kinase, SRMS, and should provide the first major clues to its function
regulation and role within the kinome. The second project involves several different
model PTKs and explores the potential to generate improved kinase specificity from a
novel approach to small molecule PTK inhibitor design.

Investigating SRMS as a unique PTK model
Upon its discovery in 1994, the SRMS kinase was erroneously labeled as a Src
family member PTK. Twenty years later, there are few studies that report any
empirical data on the enzyme’s attributes or provide any evidence of a cellular
function. Thus, the work described in this thesis began by developing an affordable,
adaptable, and reproducible system of expression and purification of the active
enzyme. The purification techniques developed for the isolation of SRMS are also
broadly applicable to other PTKs of clinical interest, representing a significant
technical achievement. Specifically, the developed methods described provide a
novel way to remove a common contaminant (GroEL), thereby improving purification
of PTK samples. Based upon this work, the project was then able to reveal the first
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major regulatory mechanism known to govern this enzyme’s activity and highlight
several other potential avenues for further investigation of this understudied PTK.

Developing novel PTK inhibitors
The second aim of this thesis explores a novel strategy for augmenting
existing small molecule inhibitors with a small library of select compounds. The goal
of this strategy is to extend the binding pocket of the inhibitors, in hopes of reaching
highly variable regions outside of the conserved ATP-binding cleft, thereby
generating enhanced specificity. The synthesis strategy that was employed in this
study was based on work performed by several other groups. In their studies, existing
inhibitors were used for the attachment of chemical adducts that were presumed to
protrude from the ATP-binding pocket. While the compounds derived by these
groups were used for affinity capture purposes, the focus of the current study was to
ascertain the feasibility of adapting this method to drug discovery, using the high
affinity inhibitor dasatinib as a model.
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Abstract:
Although recombinant expression in bacterial cells offers a convenient and
rapid way for producing proteins and enzymes for biochemical and structural
characterization, the expression and purification of each kinase often presents its
own challenges. Protein-tyrosine kinase SRMS belongs to the Brk family of kinases.
The other members of this kinase family, FRK and Brk, have been shown to regulate
cell proliferation and survival, and are associated with cancer development. Yet,
biochemically, this family has not been extensively characterized. Here we report a
procedure for the bacterial expression and purification of SRMS. To overcome the
toxicity of SRMS expression, the kinase is co-expressed with the catalytic domain of
protein-tyrosine phosphatase 1B (PTP1B). To help overexpressed SRMS fold into the
active enzyme, GroES and GroEL chaperones were also co-expressed. However,
GroEL binds tightly to SRMS, resulting in extensive GroEL contamination in purified
SRMS. The tight binding between SRMS and GroEL is disrupted by a novel washing
procedure that includes KCl, ATP-Mg complex, and casein. The purified enzyme is
activated by extensive autophosphorylation in the activation loop, and treatment
with a protein tyrosine phosphatase, or mutation of the activation loop Tyr, results in
the inactivation of SRMS. Several purified enzyme constructs and mutant forms of
this kinase were kinetically characterized, yielding regulatory insight.
Keywords: protein-tyrosine kinase SRMS; GroEL; chaperone; casein; dasatinib;
autophosphorylation
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Introduction:
SRMS, short for Src-related kinase lacking C-terminal regulatory tyrosine and
N-terminal myristoylation sites, was originally identified in mice and rats as a novel
protein-tyrosine kinase (PTK).[1, 2] Alternatively known as Srm or PTK70, the gene
encoding this kinase is also present in humans, located on human chromosome
20q13.3.[3, 4] A double deletion of the mouse SRMS gene showed no readily
apparent defects.[1] However, this gene is located on a segment of the chromosome
that is known to be frequently amplified in breast cancers and other pathologies.[58] Analysis of SRMS mRNA transcripts indicates a ubiquitous expression profile that is
especially strong in the skin, as well as regions of the brain, liver, lungs, testes, and
gastrointestinal tract.[1, 2]
SRMS and its closest homologs, Brk and Frk, are the only members of the Brk
family in humans and other mammals. This group was formerly considered part of
the Src Family Kinases (SFKs), on account of their protein sequence homology and
common domain architecture. However, conserved exon/intron organization
supports their distinction from SFKs as a related, but unique, family of kinases.[6] The
functional and biochemical nature of SFKs has been extensively characterized for
their importance in cancer biology. Like the SFKs, the oncogenic potential of Brk and
Frk has been clearly established.[6, 9] However, this role has yet to be reconciled
with evidence suggesting that each of these two BFK members can operate as a
tumor suppressor in certain contexts.[10, 11] Through ongoing functional and
biochemical studies of Brk and Frk, our understanding of this unique kinase family
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continues to evolve. Yet, how SRMS, the remaining BFK member, relates to Brk and
Frk is unknown. Since its discovery, no published studies have focused on SRMS,
despite its broad expression profile and implicit association with oncogenesis.
SFKs are regulated by two main mechanisms: autophosphorylation of the
activation loop on Y416 and C-terminal tail phosphorylation on Y527 (using chicken
Src numbering). SFKs become activated by Y416 autophosphorylation and inhibited
by Y527 phosphorylation. These opposing regulatory features work in concert to
achieve proper kinase activity.[12] SRMS and the rest of the Brk family possess an
activation loop Tyr (Y395 of SRMS) but the surrounding sequence varies significantly
amongst each BFK member and bears little resemblance to SFKs. Moreover, BFKs lack
significant features that are required for tail Tyr phosphorylation in SFKs and SRMS
does not possess a C-terminal tail Tyr at all. Given these apparent differences with
SFKs, it is unclear how either of these known regulatory mechanisms contributes to
activity in BFKs, especially SRMS.
We sought to express and purify SRMS for biochemical characterization.
Recombinant expression in E. coli is often convenient for the in vitro analysis of PTKs
because it is rapid and relatively inexpensive; but it is not without its challenges. In
the expression and purification of SRMS, we circumvented problems of toxicity and
solubility by co-expressing a protein-tyrosine phosphatase and GroES/GroEL
chaperone proteins, respectively. Tight binding between SRMS and GroEL was
dissolved by new washing procedures with ATP-Mg complex and casein. To validate
this system, we generated various wild-type and mutant kinase constructs for in vitro
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assays. The biochemical data obtained from this initial characterization of SRMS
demonstrates that this kinase is activated by autophosphorylation, providing insight
into the regulation of this poorly understood protein-tyrosine kinase family. Thus,
this system offers a convenient and reliable means to derive active SRMS that is
suitable for biochemical studies of regulation and is likely adaptable to many other
protein-tyrosine kinases. Furthermore, the unique washing procedure presented
provides a useful tool for the removal of co-purifying GroEL, a common obstacle to
the purification of a wide variety of proteins.
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Table 1.
Components of the bacterial expression system for SRMS purification.
Plasmid
b

pGEX4T1-SRMS

a

Product

Resistance

Function

GST-SRMS fusion
protein

ampicillin

Target kinase with an
affinity-tag

streptomycin

PTP 1B to reduce toxicity
of heterologous PTKs
Chaperones to increase
solubility of target kinase

pCDF-MBP-PTP1B MBP-PTP1B fusion
protein
pREP4-GroESL

GroES and GroEL

kanamycin

pRIL

argU, ileY, and leuW
tRNAs

chloramphenicol Rare tRNAs to enhance
SRMS translation

a

Escherichia coli BL21(DE3) was used as the host strain.

b

Full-length (FL), catalytic domain (Cata), and unique domain-deletion (D60) forms of
SRMS were used.

52

Materials and Methods:
Reagents and chemicals
Consumables and culture media, or media components, were purchased from
Fisher Scientific. Dasatinib was purchased as free base from LC laboratories, the PY20
anti-phosphotyrosine antibody was purchased from Santa Cruz. , and 32P-labeled ATP
was from Perkin-Elmer. All other chemical reagents were purchased from SigmaAldrich.

Molecular cloning and recombinant expression of SRMS
The full-length, Δ60 (removing unique domain), and the catalytic domain
forms of rat SRMS (NCBI: NM_001011961) were cloned from commercially available,
plasmid-encoded cDNA using custom primers. Digestion and ligation with the pGEX4T-1 plasmid was followed by transformation to our host strain. DNA sequencing
results confirmed that SRMS was properly inserted along the reading frame of the Nterminal GST affinity tag (Figure 1). Custom primers were used in site-directed
mutagenesis of WT to Y395F (activation loop Tyr to Phe) using standard QuikChange
(Agilent) protocols and confirmed via sequencing. The host strain of E. coli
BL21(DE3)-RIL was previously transfected with separate plasmids encoding PTP1B
phosphatase and GroES/GroEL chaperone proteins to reduce kinase toxicity and
promote solubility of the recombinant kinase (Table 1). Previously, this host has
proven successful for the rapid production of highly purified recombinant PTKs.[13,
14]
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Figure 1.
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Figure 1 – Expression vector design and cloning. SRMS cDNA was PCR amplified from
rat cDNA using custom primers to incorporate the sites necessary for restriction
digestion and cloning. SRMS was successfully cloned for inducible expression and
purification as GST-fusion proteins from the following constructs: pGEX-4T-1SRMSΔ60, A, does not contain the N-terminal Unique domain (first 60 residues) but
contains all other coding regions including the SH3, SH2, and catalytic domains;
pGEX-4T-1-SRMScata, B, contains the catalytic domain of SRMS and the gene’s native
3’ un-translated region (3’UTR). pGEX-4T-1-SRMS-FL was also cloned but did not yield
significant quantities of the full-length enzyme. The unique restriction enzyme cut
sites outside of the coding regions are shown (boxed), indicating their cut sites within
the vector.
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Bacterial culturing was performed while shaking at 250 rpm in 37˚C LB media
containing the appropriate antibiotics. Freshly plated colonies were used to grow
overnight cultures and, in the morning, these were diluted at least 50-fold into
500mL of pre-warmed media in two 1-liter flasks. For optimal culture and induction,
we employed the auto-induction method, described by Studier. [15] In this method,
cultures are grown shaking at 37˚C until an OD600 of 1.0-2.0 was reached, transferred
to room temperature, and then grown for about 24 hours, until the growth
plateaued (typically OD600 = ~14). Cells were harvested at 4˚C by centrifuging the
culture at 9,000 x g for 6 minutes. Cell pellets were then frozen at -20˚C overnight or
stored less than a week prior to purification of the expressed SRMS.

Optimized protein purification procedure
Cell pellets were thawed and resuspended on ice in 1/10 original culture
volume of pre-chilled PBS lysis buffer, consisting of 80 mM phosphate, 600 mM NaCl,
0.1% β-mercaptoethanol, 1 mM EDTA, and 0.01% triton X-100 at pH of 7.3. These
high phosphate and salt concentrations were found to drastically improve GST-SRMS
solubility. Following resuspension, lysozyme was added to a concentration of 0.1
mg/mL and incubated on ice for 10-20 minutes, prior to sonication. While on ice,
lysates were sonicated in four 30-second increments between setting 3 and 4.
Lysates were cleared by centrifugation at 22,000 x g for 10 min in 4°C. After reserving
a small sample for later analysis, the supernatant was then incubated with ~1mL of
pre-swollen GSH-agarose bead (Sigma) while shaking at 4˚C. After one hour, the
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lysate suspension was passed through an empty chromatography column and a
sample of the flow-through was collected and preserved for later analysis. Washing
of the column was carried out at 4˚C using 50 mL of wash buffer A (80mM phosphate,
600mM NaCl, 0.1% β-mercaptoethanol, pH of 7.3) and then followed by 40 mL of
wash buffer B (50 mM Tris, 0.1% β-mercaptoethanol, pH of 7.3).
To remove GroEL, supplementary wash buffers were used. The AMK wash
buffer was freshly prepared to contain 5mM disodium ATP, 10mM MgCl2, 150mM
KCl, 0.1% β-mercaptoethanol, and 50mM Tris at a pH of 7.3. For most effective GroEL
washing, our optimized procedure utilizes AMK washing buffer + casein. 50mg/mL
lyophilized casein was prepared as a stock solution of 1M NaOH by intermittently
vortexing at room temperature and then diluted 100-fold in the AMK washing buffer
and pH adjusted to 7.3 with HCl for a final concentration of 0.5mg/mL. GroEL was
removed from the column by re-suspending the resin with AMK + casein, incubating
for 5-10 minutes (just long enough for the bead to re-settle), and then allowing the
wash to pass through the column. This step was repeated every 10-15mL’s of
washing solution to effectively release GroEL with just 50mL of AMK/Casein buffer.
The SRMS-bound agarose was then rinsed with a final volume of 50mM Tris (pH 8) +
0.1% β-mercaptoethanol to remove lingering washing buffer components, and GSTSRMS was eluted in the same buffer, plus 10mM reduced glutathione. Protein
concentration was quantified via Bradford assay according to a standard BSA curve
prior to storage at -20˚C as diluted 40% glycerol working stocks.
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SDS-PAGE and Western Blotting
Protein purity was assessed by SDS-PAGE and Coomassie staining. Samples
were mixed with one-third volume Laemmli sample buffer containing 2.5% βmercaptoethanol, heated for 10 min at 95˚C, and centrifuged at >13,000 rpm on a
table-top centrifuge for 30 seconds prior to loading. Except where noted, SDS-PAGE
was carried out using Bio-Rad Criterion XT 4-12% polyacrylamide Bis-Tris pre-cast gels
with MOPS running buffer accompanied by pre-stained Precision-Plus Kaleidoscope
molecular weight standards. Gels were resolved for 45-60 minutes at a constant
200V before Coomassie staining for 30 minutes. Following de-staining and
equilibration in water, gels were imaged and analyzed with the Bio-Rad GelDoc
system.
For western analysis, samples were first subjected to SDS-PAGE, as described
above. Gels were equilibrated in transfer buffer and then blotted onto methanolactivated polyvinylidene difluoride (PVDF) membranes for one hour at 25V using a
semi-dry transfer apparatus. Proper quantitation of the samples was confirmed by
Coomassie staining a duplicate gel or Ponceau S treatment of the membrane.
Thorough and even transfer of the samples to the PVDF membrane was visually
verified from the spent protein gel. Membranes were immediately blocked in TBST
containing 5% non-fat milk for one hour at room temperature and then rinsed with
TBST. The membranes were immunoblotted with mouse monoclonal antiphosphotyrosine IgG (PY20, Santa Cruz) and HRP-conjugated mouse IgG antiserum,
with washing in TBST in between the primary and secondary antibody treatments.
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Blots were examined after 5 minutes treatment with ECL+ substrate (GE Healthcare)
by exposure to film.

Kinase Assays
All kinase assays were carried according to previously published protocols.
Duplicate 40µL samples, each containing the appropriate enzyme/sample
concentration and 1mg/mL polyE4Y substrate, were prepared in kinase buffer (75mM
EPPS, pH 8.0 + 5% glycerol + 0.005% Triton X-100) prior to the assay. Reactions were
initiated by addition of 10µL ATP-Mg cocktail for a final concentration of 200μM
ATP/[γ-32P]-ATP and 12 mM MgCl2. The specific activity (usually between 750 and
1,500 dpm/pmol) of each assay’s reactions was kept constant. All reactions were
incubated at 30˚C for 20 min, then 35 µL of each reaction was spotted onto 1- x 2-cm
strips of filter paper, which were then washed in 5% trichloroacetic acid (65˚C,
constant stirring). The 32P incorporation into PolyE4Y was quantified using a Beckman
Coulter LS-6500.[16]
For kinase assays designed to determine the Km, the reactions were setup as
described above except the concentration of ATP in each reaction was varied (but
not the specific activity). To determine inhibitor IC50’s, dasatinib was dissolved in 10%
DMSO, diluted in series, and included within the kinase reactions. For kinetic analysis
of turnover, Km, and IC50 determination, each kinase assay was performed in
duplicate and repeated at least three times. All calculations and data treatment of
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assay results, including double reciprocal plots and linear regression analysis, was
carried out in Microsoft Excel.
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Results and Discussion:
Recombinant expression system for SRMS
Currently, the only published reports of SRMS enzymatic activity utilize
commercially produced wild-type catalytic domain from insect cell expression
systems. As we aim to characterize SRMS regulation, we opted to develop a bacterial
expression system that would enable efficient mutational analysis. To this end, we
cloned the coding sequence of SRMS into the multiple cloning site of pGEX-4T-1 to
express the kinase as a fusion protein of GST-SRMS (Figure 1). However, there are
several challenges to expressing and purifying protein-tyrosine kinases from a
bacterial system.
Some PTKs are toxic to bacterial hosts because they tend to phosphorylate
many native proteins. Co-expression of a protein tyrosine phosphatase, such as
PTP1B, often helps to overcome this problem.[17, 18] Additionally, expression in
bacteria may cause recombinant enzymes to fold incorrectly, leading to insolubility
and limiting activity. This problem is frequently alleviated by the co-expression of
chaperone proteins, such as GroES/GroEL. Finally, the frequency of codon usage
varies substantially from human to bacteria and this is thought to have negative
influence on the total yield of target proteins. A PTK with many codons that are rarely
used in bacteria may not be well expressed due to insufficient host production of
certain aminoacyl-tRNA.
To mitigate this problem, host strains are often complemented with plasmids,
such as pRIL, which elevate rare tRNA for Arg, Ile, and Leu, to greatly enhance
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expression.[19] With these considerations in mind, we co-expressed SRMS with
PTP1B, GroES/EL, and Arg/Ile/Leu tRNAs to increase the quantity and quality of the
recombinant enzyme produced by the E. coli BL21(DE3) host strain. The components
of this system are detailed in Table 1, and similar expression strategies have been
used in the past for SFKs, as well as other kinases.[13, 14]

Purification of active SRMS
Our initial attempts using this system relied on traditional IPTG induction and
GST affinity purification. This, however, resulted in low yields and the co-purification
of significant amounts of the chaperone GroEL alongside the kinase in the eluted
fractions. We then switched to an auto-induction protocol, proven to increase the
yield of many recombinant proteins.[15] Using this method greatly enhanced the
apparent solubility and yield of SRMS; however, the chaperone impurity remained
problematic, despite extensive washing (over 200 mL of wash buffers A and B).
Co-purification of chaperones is a common phenomenon and often occurs
despite optimization of induction and purification conditions. In these instances,
dissociation of the complex is most often readily achieved by introducing ATP-Mg2+
and/or denatured protein to various steps in the purification. The ATP-Mg2+ is
thought to induce conformational changes of the chaperone, promoting the release
of bound protein. However, published literature lacks a procedure that is suitable for
all PTKs.
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In the purification of ITK, a Tec family kinase, the Andreotti lab, encountered a
similar problem. They found that adding potassium (150 mM KCl) to a solution of
ATP-Mg2+ (AMK washing buffer) effectively released enough of the bound GroEL to
attain sufficient ITK purity.[18] We adapted and optimized this protocol for the
purification of SRMS.
As seen in Figure 2, GroEL (~60 kD) appears to be the dominate protein within
the soluble cell lysate, shown in lane 1. A significant portion of GroEL appears to be
removed during the initial stages of purification, as evidenced by lane 2, which
contains the unbound lysate column flow-through. Following extensive application of
wash buffers A and B (200 mL total), until no protein can be detected from the
column flow-through, the column was stoppered, moved to room temperature, and
5 mL of AMK solution was used to re-suspend the resin. After 5-10 min incubation,
the stopper was removed and the first 0.5 mL of the wash buffer flow-through was
collected for analysis, followed washing with an additional 25 mL AMK buffer. This
incubation and wash step was repeated six more times. Examining these wash
fractions (lanes 3 – 9), it is clear that the AMK solution removes a significant amount
of GroEL that wash buffers A and B were unable to remove. After approximately 200
mL of AMK wash (lane 9), very little GroEL is cleared from the column. However,
upon elution of GST-SRMS with 10mM reduced glutathione, lanes 10 – 12, it is clear
that the AMK wash was only partially effective at removing GroEL and its efficacy
appears to increase with respect to the volume of buffer applied to the column.
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Figure 2.
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Figure 2. Purification of GST-SRMS using existing purification procedure. As described
in the Materials and Methods section, a previously published procedure was adapted
for our initial attempts to purify SRMS. Proteins from various steps of the purification
were sampled (20 µL) for separation by SDS-PAGE and stained with Coomassie Blue
for analysis. Lane 1, soluble cell lysate; lane 2, flow-through from initial loading; lanes
3 – 9, consecutive washing steps (30 mL each) with AMK buffer; lanes 10 – 12,
fractions eluted with 10mM GSH elution buffer; lane M, molecular weight markers
labeled by size (kD).
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These results lead us to seek out additional wash buffer additives to more
effectively remove the chaperone protein. Several studies have suggested that
casein, a common milk protein, can interact with GroEL through hydrophobic
interactions to promote specific molecular rearrangement and facilitate the
binding/release of ATP/ADP. Yet, to date, no purification protocol has made use of
casein as an effective washing reagent.[20-22] In light of these reports, we
experimented with casein at various points within the standard GST-tag purification
procedure, including it in the lysis buffer and as a supplement to normal washing
buffer. Following extensive washing with buffers A and B, wash buffer B + casein was
applied to the column. A sample of this wash fraction was run in lane 4 of Figure 3A.
In this lane, little to no GroEL appears to have been cleared from the resin, which
indicates that either casein in the wash buffer is unable to displace GroEL, or that
casein in the lysis buffer had prevented the chaperone from ever binding GST-SRMS.
To investigate further, the residual casein was removed by washing with buffer B
(lane 5) and then washed with AMK buffer. Since the AMK wash was shown to be
partially effective at clearing GroEL from the column (see Figure 2), the absence of
the contaminant from this fraction would indicate that casein is at least partially
effective at preventing GroEL from binding the column. However, GroEL is clearly
released by this AMK wash (lane 6) indicating that a significant amount of the
chaperone remains on the column. From these results, it can be concluded that
casein, on its own, is ineffective at preventing or disrupting the interactions of GroEL
with both free and column-bound GST-SRMS.
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Figure 3.
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Figure 3. Optimization of washing to remove GroEL. A. Casein was added to the
standard lysis and wash buffers (0.5 mg/mL each) and the GST-SRMS purification
procedure was followed as described in Materials and Methods, stopping short of
elution. 20 µL samples of each step were taken for analysis by SDS-PAGE and
Coomassie Blue staining. Lane M, molecular weight markers; lane 1, insoluble cell
pellet; lane 2, soluble cell lysate; lane 3, flow-through from initial loading; lane 4,
washing buffer + casein; lane 5, washing buffer; lane 6, AMK washing buffer. B.
Following thorough AMK washing, GSH-agarose bound by GST-SRMS was divided into
four different spin columns for wash buffer component optimization, prior to elution
with 10mM GSH elution buffer. The wash and eluted fractions of each sample were
then examined via SDS-PAGE and Coomassie Blue staining. Sample 1, washed with
AMK buffer; sample 2, washed with AMK buffer + 0.5 mg/mL casein; sample 3,
washed with AMK buffer + 2M urea; sample 4, washed with 2M urea.
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Hypothesizing that ATP may be required for casein to effectively interact with
GroEL, we investigated casein’s prospective use in the context of the AMK washing
buffer procedure. GSH-Agarose resin, bound by GST-SRMS, was washed extensively
with AMK buffer. 100µL of this pre-washed resin was loaded into spin columns and
further subjected to washes of the following conditions: 1) AMK, 2) AMK + 0.5 mg/mL
casein, 3) 2M urea, or 4) 2M urea + AMK. Figure 3B reveals both, proteins that are
washed off (top) and proteins that remain bound to the column (bottom), following
these supplementary washes. The sample that was washed with additional AMK
buffer shows no further GroEL is released by this method (top panel, lane 1). Thus, as
expected, the corresponding eluted sample contained a significant amount of GroEL
impurity (bottom panel, lane 1). At the concentration used, urea has been shown to
mildly destabilize the structure of GroEL and was thus used in an attempt to
differentially elute it from the column. Unfortunately, the urea washes appeared to
elute significant amounts of GST-SRMS alongside GroEL (top panel, lanes 3 and 4).
The AMK + casein wash, however, released a substantial amount of GroEL with little
to no SRMS loss (top panel, lane 2). As indicated by the eluted fractions (bottom
panel, lane 2), the combination of casein with AMK buffer appears to preferentially
remove GroEL to drastically improve the ratio of SRMS to GroEL.
Based on these results, we have devised an optimized procedure that is
described in detail within the methods section of this report. In summary, plasmids
encoding GST-SRMS, GroEL/GroES, and PTP1B were transformed into E. coli
BL21(DE3)-RIL, grown at 37˚C in liquid culture, and then induced at room
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temperature via auto-induction. Standard GST affinity purification is then used along
with a modified washing protocol that uses a novel AMK + casein buffer for removal
of bound GroEL. GST-SRMS can then be eluted from the column, free of any
significant impurities. Pooled fractions often contain 2 – 5 mg of active enzyme from
half a liter of culture, enough for >1,000 assay reactions, without the need for
additional concentration or re-folding steps. SRMS can be stored in 40% glycerol at 20˚C for more than a year without significant loss of kinase activity. This strategy was
used to purify the catalytic domain and Δ60 (SH3-SH2-Kinase), as well as their
mutants (see Figure 4 and Table 3).

70

Figure 4.
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Figure 4. Optimized SRMS purification. GST-SRMS was purified as described in the
Materials and Methods and samples from various points of the purification were
analyzed by SDS-PAGE and Coomassie staining. A. Wild-type catalytic domain of SRMS
purification: lane M, molecular weight markers; lane 1, 50µg insoluble cell pellet; lane
2, 50 µg soluble cell lysate; lane 3 50 µg flow-through lysate; lane 4, 20 µL standard
wash step; lane 5, 20 µL from AMK wash step; lane 6, 20 µL from final buffer wash
step; lanes 7-10, 20 µL of the peak eluted fractions (*=SRMS). The peak eluted
fractions from B. Equimolar amounts (3.5 pmol) of the eluted fractions of GST-SRMS
purifications were run together on SDS-PAGE for comparison following Coomassie
Blue staining. Lane M, molecular weight markers; lane 1, WT catalytic domain; lane
2, Y395F catalytic domain; lane 3, WT Δ60; lane 4, Y395F Δ60.
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Table 2.
Summary of SRMS purification
Total

Total
Step
Lysate
Elution

protein
(mg)

a

1,027
5.6

Specific activity

b

activity

-1

-1

(nmol min )
.01
16.74

-1

(nmol min mg )
-6

9.29x10
2.99

Yield
(%)

c

Purification
(fold)

100

1

1,674,000

321,842

a

SRMS was purified from 500 mL bacterial culture as described in Materials and
Methods.

b

The SRMS kinase activity was assayed using PolyE4Y as the substrate.

c

The cell lysate contains significant amounts of PTP1B, a protein tyrosine
phosphatase.
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c

Kinetic characterization of SRMS
To establish our purification protocol as a viable means of producing active
enzyme, we characterized the kinase activity of the catalytic domain. Kinetic analysis
of SRMS was conducted with the generic substrate polyE4Y (heterogeneous peptide
mixture with a 4:1 ratio of Glu and Tyr) and we determined a kcat of 26 min-1 (Table
3). Enzyme turnover from multiple purifications were in good agreement. As no
physiological protein substrates have yet been reported for SRMS, a direct
comparison of catalytic potential is perhaps best judged by its Km of ATP, the
universal PTK substrate. As determined from the double-reciprocal plot of activity vs.
ATP concentration (Figure 5) the Km ATP was determined to be 40µM. This value is
significantly lower than those previously determined for Csk (~150µM) and Src
(~100µM). Taken together, the kinetic data clearly indicates strong catalytically
activity of SRMS, thus validating our purification methods.
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Figure 5.
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Figure 5. Enzyme kinetics of the purified catalytic domain of SRMS. For KM of ATP
determination, 2.66 nM of SRMS was assayed with concentrations of 20, 25, 35, 50,
32

100, and 200 mM P labeled ATP using 1 mg/mL PolyE4Y as substrate.
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Table 3.
Enzymatic activity of purified SRMS
SRMS

a

b

Cata WT
Cata Y395F
D60 WT
D60 Y395F
a
b
c

-1

Turnover (min ± std.dev.)
26.10 ± 0.62
3.12 ± 0.27
1.06 ± 0.10
0.26 ± 0.03

Purified as GST-fusion proteins.
Using PolyE4Y as substrate.
Y395 corresponds to the activation-loop Tyr.
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SRMS autophosphorylation
Most protein-tyrosine kinases are known to autophosphorylate on the Tyr
residue of their activation loop, and this phosphorylation tends to activate a kinase.
The specific level of this activation, however, is highly variable from one kinase to
another and ranges from non-detectable to several hundred-fold. Since little is
known of BFK regulation, and because the purification procedure for SRMS required
extensive incubation in the presence of ATP-Mg2+, it was important to assess how
this procedure affected the level of SRMS phosphorylation, and any resulting
implications for the overall kinase activity. To fully address this issue, we first
expressed and purified an SRMS mutant containing a Phe instead of Tyr at the
autophosphorylation site (Y395F). Kinase assays from various purifications indicate
that this mutant form of the catalytic domain displays a kcat of 3 min-1, 11.5% of the
wild-type activity (Table 3). This result suggests the possibility that this form of WT
SRMS is activated by autophosphorylation, during the purification. However, we
cannot exclude the possibility that the mutation of the wild-type Tyr to Phe could
have directly affected the kinase activity. To further clarify this result, we then tested
how incubation with ATP-Mg2+ or a protein tyrosine phosphatase affected the Tyr
phosphorylation level of SRMS and the Y395F mutant, as well as their corresponding
kinase activities.
Shown in Figure 6A, purified WT SRMS catalytic domain (273 µg/mL) was
incubated with either kinase buffer (negative control), 200 µM ATP and 12 mM Mg2+,
or PTP1B for 0, 20, or 60 minutes. The amount of PTP1B was carefully determined so
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that, upon dilution for the kinase assay, phosphatase activity was insignificant. To
further reduce the chances of PTP1B confounding this experiment, each kinase
reaction was performed under non-reducing conditions which are catalytically
unfavorable to phosphatases. The protein level in the treated samples was calculated
based on pre-determined protein concentrations and molecular weights, and
confirmed by SDS-PAGE and Ponceau S staining (bottom panel). The Tyr
phosphorylation level in the samples was determined by western blotting with PY20
anti-phosphotyrosine antibody (middle panel). The kinase activities of the treated
samples were determined by the kinase activity assay (graphed, top panel). In this
series of experiments, the control treatment and incubation with ATP-Mg did not
change SRMS Tyr phosphorylation level, nor the kinase activity. However, incubation
with PTP1B dramatically decreased Tyr phosphorylation and kinase activity levels.
These results together indicate that purified SRMS is fully phosphorylated and
activated. These same experiments were performed using the Y395F form of SRMS.
As seen in Figure 6B, the Y395F mutant displays a much lower level of Tyr
phosphorylation. Although a low level of phosphorylation suggests at least one
additional site of autophosphorylation, treatment with PTP1B failed to decrease the
kinase activity level of Y395F SRMS. Overall, by comparison of the antiphosphotyrosine blots and kinase activities from each treatment of the enzymes, it is
apparent that the kinase activity of SRMS strongly correlates to Tyr395
phosphorylation level. The WT SRMS kinase activity was reduced from 16.8 min-1
(negative control, 60 min) to approximately 3.2 min-1 (60 min, PTP1B treatment). This
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represents more than five-fold reduction in activity, despite incomplete dephosphorylation (as indicated by the western blot) and any autophosphorylation that
may have occurred during the kinase assay. Altogether, the results seen in Figure 6A
and B indicate that activation by autophosphorylation of WT SRMS is achieved,
primarily, through phosphorylation of Tyr 395 in the activation loop. Furthermore,
these assay results (and several not shown here) suggest that autophosphorylation of
the activation loop tyrosine results in approximately 5- to 10-fold activation of SRMS
kinase activity.
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Figure 6.
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Figure 6. SRMS autophosphorylation of the activation loop Tyr, Y395. The WT (A) and
2+

Y395F (B) GST-SRMS catalytic domains were pre-treated with either ATP/Mg ,
purified PTP1B, or kinase buffer (as a control) for 0, 20, or 60 minutes prior to analysis
of phosphorylation and activity. To detect phosphorylation, samples were run on SDSPAGE before being transferred to PVDF for western blotting with antiphosphotyrosine antibody (PY20). Membranes were stained with Ponceau S to
ensure even sample loading and transfer. The samples were also analyzed for their
kinase activity using

32

P-ATP and PolyE4Y (results in bar graphs) for comparison.

Western analysis of untreated WT and Y395F GST-SRMS Δ60 was also carried out, and
kinase activity was determined (C).
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Characterization of Δ60 WT and Y395F SRMS kinase activity toward polyE4Y
yielded turnovers of 1.06 and 0.26 min-1, respectively (Table 3). While substantially
less active than the catalytic domain, these values suggests a similar pattern of
activation by autophosphorylation. To examine whether the difference in kinase
activity between WT and Y395F Δ60 also correlates to phosphorylation levels, we
blotted the WT and mutant forms as described above. Western blot analysis of Δ60
with anti-phosphotyrosine antibody, shown in Figure 6C, confirms a substantial
decrease in phosphorylation of the Y395F SRMS. This is consistent with our results of
the catalytic domain and suggests this mode of activation by autophosphorylation is
not intrinsically inhibited by the SH3 or SH2 domain.
Additionally, this figure once again demonstrates that SRMS can be
phosphorylated on Tyr residues outside of the activation loop. Whether this
phosphotyrosine has any impact on the dramatic difference in observed activities of
the Δ60 and the catalytic domain forms of the enzyme is not apparent from our
analysis. It is important to note that this study cannot rule out many potential
artifacts that could interfere with enzymatic stability, stemming from the inclusion of
the SH3-SH2 domains or lack of the unique domain in the Δ60 SRMS construct. The
apparent suppression of Δ60 activity is none the less intriguing, especially considering
that Brk, Frk, the entire Src family, and many other PTKs are negatively regulated by
intramolecular SH3 and SH2 domain interactions in phosphotyrosine dependent and
independent mechanisms. However, further investigation is clearly needed to
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determine whether any of these conserved inhibitory features may be present in
SRMS.

Dasatinib inhibition of the active and inactive forms of SRMS
When studying kinases such as SRMS, inhibitors often serve as invaluable
research tools. Dasatinib is a broad spectrum PTK inhibitor originally developed to
target the Abl catalytic domain, with broad clinical application to cancer therapies.
With a sub-nanomolar KD and IC50, dasatinib has been shown bind to the active form
of Abl.[23] This binding mode has been reaffirmed by several other kinase structures,
particularly Src, which show comparable affinity to the active conformation.
Molecular modeling approaches, however, predict that dasatinib should also be able
to bind the active site. Many publications continuously cite dasatinib’s ability to bind
both inactive and active conformations, despite contrary structural evidence and
without any biochemical analysis to support these claims.[24] Because of the
inherent difficulties of studying this problem with ABL, these controversial claims
persist and have complicated rational drug design efforts. As dasatinib has been
shown to bind SRMS with a KD of 13nM, we sought to examine the inhibitor’s
capacity to discriminate between the enzyme’s active and inactive forms. Also, if this
analysis confirms the suspected inhibitory effects of dasatinib upon SRMS, it will also
validate dasatinib’s potential use in the investigation of this understudied kinase.
The phosphorylation of the activation loop does not always lead to activation
of a kinase, as many kinases differ in this regard. All kinases have the ability to adopt
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an active conformation, independent of activation loop phosphorylation, with
varying efficiency. In particular, ABL appears to convert between these
conformations equally well, regardless of autophosphorylation. Because of ABL’s
inability to become activated in this manner, it is difficult to determine whether
dasatinib truly binds either form, or just active conformation kinase. As we have
recently demonstrated the capacity of SRMS to achieve activation via
autophosphorylation, we subjected both active and inactive forms of the kinase to
dasatinib treatments while assaying their kinase activities toward PolyE4Y. Our
analysis results (Figure 7) of the inhibitor toward the catalytic domain of SRMS
revealed an IC50 value for the Y395F mutant of 10 nM and the active/phosphorylated
WT was found to be 3.5 nM, about a three-fold difference. This clearly demonstrates
a preference for the active form, in support of the structural data concerning
dasatinib. These values also serve to validate the use of dasatinib as potentially
valuable tool or probe, in addition to phosphorylation levels of Y395, for further in
vitro characterizations and functional analysis of active SRMS.
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Figure 7.
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Figure 7. Dasatinib inhibition of the active and inactive forms of SRMS. The activity
-1

(turnover, min ± standard error) of WT and Y395F SRMS catalytic domains were first
assayed without inhibitor: WT = 29.15 ± 0.28; Y395F = 3.12 ± 0.15. The activity of
each enzyme was then measured in the presence of 160, 16, 1.6. 0.16. and 0.016 nM
dasatinib and graphed as a percentage of the uninhibited activity to determine
dasatinib’s IC50 : (•) WT = 3.5 nM; (Δ) Y395F = 9.0 nM.
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Abstract
Kinase inhibitors frequently suffer from a lack of specificity, most likely due to
the high degree of conservation within their targets’ ATP binding pockets. We
reasoned that specificity may be developed by extending the inhibitor out from the
traditional binding pocket to interact with more diverse sites. To test this hypothesis,
derivatives of dasatinib were synthesized via esterification with one of 25 small
molecules, thereby increasing the chemical diversity of the kinase inhibitor. Our
approach generated numerous inhibitory compounds with enhanced kinase
selectivity. Moreover, several unique characteristics of these inhibitors were
explored for their potential utility as pro-drugs or research tools. Together, these
findings highlight the great potential for this novel strategy with broad applications
for the design and development of kinase-specific inhibitors.
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Introduction
Protein tyrosine kinases (PTKs) are involved in numerous pathologies,
including many cancers. Subsequently, PTK inhibitors have proven to be invaluable
research and therapeutic tools. Current PTK inhibitors are mostly ATP analogs and
are quite limited with regard to their specificity.1 Ideally, such molecules would be
able to target the aberrant kinases without interfering with normal physiological
kinase signaling. This problem stems from a lack of structural diversity in the
ATP/inhibitor binding pocket, similar in all kinases. The potent tyrosine kinase
inhibitor (TKI) dasatinib (BMS-354825) is a case in point. It binds to the ATP binding
site of many PTKs and is a potent, broad spectrum PTK inhibitor.2
The discovery and development of dasatinib was announced by Bristol-Myers
Squibb in 2004 as an orally administered anticancer compound.3 In 2006, the
company was granted tentative FDA approval for dasatinib, via the accelerated
review process, and began marketing the drug as Sprycel®.4 Initially, approved
indications for use applied only to adult patients diagnosed with either Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase, or
Ph+ acute lymphoblastic leukemia (ALL), who were intolerant or resistant to standard
imatinib (Gleevec, by Novartis) treatment. In 2010, full approval was granted for the
treatment of imatinib resistant Ph+ ALL/CML, once further safety and efficacy was
established. This extended the approved indications to include less developed Ph+
CML, still in the accelerated or blast phases.5

94

The Ph+ profile of many ALL/CML cancers is readily observed via standard
karyotype, as it involves a specific translocation between chromosomes 9 and 22.6
This chromosomal aberration induces abnormal expression of a BCR-Abl fusionprotein. The fusion of the two proteins disrupts the normal regulatory mechanisms of
each. In particular, the loss of the N-terminal domains of Abl removes key
components of substrate recognition, cellular localization, and catalytic inactivation.
The truncated kinase is responsible for creating a highly distorted pattern of
phosphorylation, upsetting normal cell signaling dynamics, and leading to the
oncogenic progression of ALL or CML. TKIs, such as imatinib and dasatinib, inhibit
cancer progression by blocking the kinase activities of BCR-Abl and/or other kinases
that are known to contribute oncogenic signaling, such as Src Family Kinases (SFK).
Dasatinib inhibits SFKs, BCR-Abl, c-KIT, EphA2, PDGFR-beta kinases with
nanomolar or sub-nanomolar IC50.5 It has been also crystalized as a bound ligand to
the Abl, BMX, BTK, EphA4, Lyn, p38alpha, p38MAP, and Src kinases.7-14 The common
manner in which it binds to each of these kinases, suggests it should be similar for
many other kinases, too. This may, in part, explain side-effects of the compound at
clinical dosage. Moreover, the clinical dosage, itself, may be limited by toxicity due to
off-target kinase inhibition. This can lead to the persistence of cancer in small, drugresistant populations and, ultimately relapse of patients who were previously in
remission. In some patients, mutations arise during the course or treatment, or
before. In all of these cases, where resistance has developed, alternative therapies
must be sought.
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These problems associated with balancing toxicity with effective dosage are
not unique to dasatinib. All currently available TKIs are expected to lose effectiveness
at some point to restart disease progression. From this perspective, it seems obvious
that greater kinase specificity should be a top priority in the development of novel
therapeutic inhibitors. However, it seems likely that many kinases share too great a
degree of similarity to reasonably expect true specificity from ATP analogs, even from
drugs with the potency of a molecule like dasatinib.
Outside of the ATP binding cleft of PTKs there are several regions of great
variability amongst kinases, as demonstrated in Figure 1. Outside of the kinase’s
active site and lacking a defined binding pocket, these regions have garnered little
attention as drug targets, on their own. However, by extending inhibitors from the
ATP binding pocket into nearby variable regions, inhibitors may obtain greater
capacity for specificity, through new interactions, while maintaining much of their
affinity via ATP binding cleft interaction. Conveniently, certain PTK inhibitors,
including dasatinib, bind to the kinase in such a way that a small portion of the
molecule resides just outside of the ATP binding cleft. It has been demonstrated
previously that chemical modifications to these drugs can be made to this position to
facilitate attachment of chromatographic resins for affinity purification.15-17 By
addition of small molecules to the dasatinib scaffold, it may be possible to extend the
binding site to include regions of the kinase that are more diverse in order to impart
greater potential PTK specificity.
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We sought to evaluate this strategy by linking dasatinib to a series of small
molecule adducts via esterification reactions.

Following favorable molecular

modeling results, we employed this technique to build a small library of 26
compounds (Figure 2). A diverse panel of non-receptor PTKs (including Csk, Abl, and
Src) served as a basis for evaluating these compounds in terms of their potency and
specificity. Several selected compounds were then further explored to reveal some
unique properties and potential applications of these novel inhibitors.
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Figure 1.
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Figure 1. Structural elements of inhibition. Dasatinib inhibition of kinase activity is
mediated by molecular interaction with highly conserved residues from the ATPbinding cleft of the catalytic domain. (A) The MUSCLE aligned protein sequences from
the catalytic domains of Abl, Csk, Src, and Lyn illustrate the level of conservation
throughout various regions of the catalytic domain among these diverse PTKs. The
darker shaded portions of the alignment indicate greater conservation. The ligandbound crystal structure of Lyn (B) demonstrates how dasatinib is docked within the
catalytic domain. The inhibition of kinase activity is achieved via molecular
interaction with amino acids of the ATP-binding cleft. These residues are displayed in
stick form in the structure and also indicated by black arrowheads within the
alignment. The region of the catalytic domain between the end of α-helix D and the
beginning of α-helix E is boxed within the alignment and structure to highlight its
inherent variability and proximity to the dasatinib binding site.
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Figure 2.
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Figure 2. Dasatinib derivatives. Dasatinib free-base (LC laboratories) was used as a
scaffold for the attachment of various small molecules.
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Results
Modeling
In order to establish the theoretical feasibility of binding and rule out any
obvious steric hindrance, selected dasatinib derivatives were modeled and docked
into the crystal structure of a PTK. The Lyn kinase (PDB code: 2ZVA) was chosen as it
is a member of the clinically relevant SFKs.10 2ZVA is a particularly good candidate
among SFKs because it is nearly complete with few gaps and very good resolution.
The resolution and completeness of this structure outside of the dasatinib binding
pocket was essential, given that the additions to the core compound would
potentially interact with a region outside the traditional binding pocket. Kinase
catalytic domains are known to adopt at least two distinct confirmations within
crystal structures, active or inactive. To ensure that the proper conformation was
used in docking studies, the structure (already bound by dasatinib) was edited to
remove the co-crystallized ligand before modeling the compounds. In this manner,
the parent compound could serve as a reference and control to ensure docking
parameters were functioning properly.
We modeled each of the 20 common amino acids, along with addition of
phosphotyrosine, as carboxyesters of dasatinib to establish the feasibility of our
approach. This small collection of potential derivatives could be conveniently
synthesized and represent of a variety of sizes and physical properties, while keeping
computational cost low (by virtue of few rotatable bonds to calculate). Combining
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accuracy and ease of use, we chose Autodock Vina to perform our in silico modeling.
Autodock Vina’s performance in docking has been relatively well established and its
algorithms require no assumptions to be made concerning the ionization of sidechains.18, 19
All of the compounds were docked and the top conformational hits of each
were scored and ranked by the calculated binding energies that were reported in the
program’s docking summaries (Figure 3). The reference control, dasatinib, showed
little deviation from the original crystallized ligand when its coordinates were
superimposed. Additionally, the core dasatinib portion of each derivative was also
nearly identical. We calculated a KD of 8.3nM from the binding energy of -10.9
kcal/mol, which is in good agreement with the experimentally determined value of
3nM by our later assays. The calculated binding energies of all derivatives are within
0.9 kcal/mol of the dasatinib control.
The favorable binding energies of the docking simulations helped to support
the notion that small molecules would not likely prohibit dasatinib binding when
linked via esterification. These adducts were predicted to extend out from the ATP
binding pocket with little, if any, disturbance to the normal mode of dasatinib
binding. Furthermore, the favorable increases in calculated affinity in some dockings
suggested that some small molecules could favorably interact with portions of the
kinase, outside the ATP binding pocket.
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Figure 3.
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Figure 3. Inhibitor screening results. Results of screening of compounds at a fixed
concentration against each of the panel PTKs. The activity of uninhibited enzyme was
compared to dasatinib-inhibited enzyme activity to establish a baseline of inhibition.
Each of the compounds were then compared to dasatinib inhibition for each enzyme.
Bars above the x-axis show increased potency, while those below indicate a
decreased capacity to inhibit the kinase, relative to dasatinib.
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Design and Synthesis
Encouraged by the docking studies, we derivatized dasatinib by chemical
esterification with various amino acids (for reasons stated above) using the protocols
detailed in the methods section. Alongside these compounds, additional derivatives
were synthesized by esterification with several fatty acids. These particular
derivatives were chosen to evaluate their potential use as linkers to sites more distal
to the ATP binding pocket. From this approach, 25 compounds were successfully
synthesized and purified including 14 amino acid and 10 fatty acid adducts of
dasatinib (Compounds 2-25). Compound 26 was later synthesized as a fluoresceinglycine ester to further demonstrate the utility of such chemical derivatives.
Synthesis yields were good, overall, ranging from 70-95%.

Compound Screening
Each of the amino acid and fatty acid inhibitors were screened at a fixed
concentration against Abl, Csk, and Src PTKs. Their percent inhibition relative to
dasatinib was then determined. The results of this screening (Figure 3) offered insight
as to the potency of each adduct, relative to dasatinib. Moreover, this relative profile
could be compared between Abl, Csk, and Src kinases. Thus, this screening helped to
highlight potential patterns of enhanced or diminished inhibition relating to the type
of adduct.

106

In general, fatty acid-derived compounds dramatically decreased inhibitor
potency. Of these compounds, only 16 (-C2) inhibited comparably to dasatinib. Each
of the remaining derivatives achieved less than 60% of dasatinib’s inhibition toward
each kinase. The screening profile of compound 24 (-C11NH2), when compared to
that of similarly sized compounds (-C10, -C12, and -C11SC2), suggests that
hydrophobicity, not size, accounts for much of these inhibitors’ reduced potency.
Furthermore, losses in potency due to long, hydrophobic chains may be recovered, at
least in part, by linkage to a polar functional group (like –NH2).
The amino acid derived compounds showed significantly greater potency over
fatty acyl derivatives, with the exception of compound 13 (-C). Compound 15 (-E)
also displayed a significantly reduced potency when compared to other amino acid
derivatives. Compound 7 (-R) appeared to be the most potent of the inhibitors tested
against all three kinases. We scrutinized docking results to identify a plausible
explanation for this apparent increase in potency. Interestingly, the side-chain
guanidium group of compound 7 (-R) was predicted to form a hydrogen bond with
the backbone of the kinase, just outside the ATP binding-cleft.
The major changes in potency by our derivatives are interesting and perhaps
informative, but are not the main focus of our study. Since we endeavor to isolate an
active agent with altered kinase selectivity, the compounds’ variable potency
between kinases was our greatest concern. Compounds 21 (-C16), 24 (-C11NH2), and
23 (-C20) showed a significantly decreased capacity to inhibit Abl, as compared to the
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other kinases. Compound 7 (-R), however, demonstrated its potency gains were
greatest for Abl. Additionally, compound 16 (-C2) displayed significantly increased
potency toward Csk when compared to Abl and Src. The screening assay’s sensitivity,
however, limited the extraction of further selectivity results.

IC50 determination
The screening, while relatively rapid, is not particularly sensitive and, thus, is
limited in the task of identifying changes in kinase specificity. We further
characterized the inhibition of selected compounds via IC50 assays toward each of the
kinases. First, compound 7 (-R) was chosen because it was one of the best
compounds screened for each of the kinases in terms of potency and selectivity. We
then chose compounds 3, 13, and 15 (-A, -C, -E) to use as a basis for comparison and
to tease out potential differences in selectivity.

For the fatty acid-derived

compounds, we again chose to compare the most potent compound, 16 (-C2), one
longer chained derivative (21, -C16), two moderately long-chained compounds (17/C8, 18/-C10), and the potential linker compound 24 (-C11NH2) for further

investigation.
The results of the IC50 assays, summarized in Table 1, reflect the potency of
the compounds toward each of the PTKs. As predicted by the screenings, compound
7 (-R) displayed increased potency against all kinases with an average 37% decrease
in IC50 compared to dasatinib. The greatest gain in potency was observed for Abl by
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compound 7 (-R) with an IC50 of 0.45nM as compared to the 0.75nM value for
dasatinib, representing a 42% decrease. Conversely, compound 13 (-C) was the worst
performing of the amino acid derivatives with IC50’s ranging from 1.7 - 5.3x higher
than dasatinib toward our PTK panel. Interestingly, compound 15 (-E) performed
about as well as compound 3 (-A), despite the latter showing possible signs of greater
potency in the screenings.
To garner more quantitative insight into potential gains or losses in enzyme
selectivity, the IC50 of each compound toward a particular kinase can be compared to
the IC50 of the same compound for another kinase, in the form of a ratio. For
example, the IC50 of dasatinib is 7nM for Csk and 0.37nM for Src, giving a C/S ratio of
18.9, clearly indicating specificity toward Src. When comparing Abl and Src, however,
a A/S ratio of 2.1 for dasatinib implies that the compound inhibits both kinases in
rather non-selective fashion. In this manner, ratios greater than 10 or less than 0.1
reflect IC50‘s that differ by more than an order of magnitude, and the inhibitor is
generally considered to be selective or specific for the kinase with the lower IC50.
Comparisons of the specificities for each of the compounds toward Csk shows
that two compounds, 7 (-R) and 16 (-C2), showed little change in their preference for
Src (17.6 A/S and 16.7 C/S, respectively).

However, each of the remaining

compounds increased their preference for Src dramatically with C/S IC50 ratios of 30.0
or higher. The highest selectivity ratio obtained in our study, 91.4 C/S, was from this
group and belonged to compound 18 (-C10) with an IC50 for Csk = 3.2µM compared to
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35nM for Src. This marks a difference of almost two orders of magnitude between
the IC50 values. Additionally, each of these compounds displayed increased selectivity
toward Src, as compared with Abl. Of particular note, compound 15 (-E) and
compound 13 (-C) demonstrated the largest gains (10.2 and 10.3 A/S IC50 ratios).
These two dasatinib derivatives represent the only bona-fide Src specific inhibitors in
our dataset, as they possess IC50’s at least an order of magnitude higher for both Abl
and Csk, and present a significant increase in kinase specificity when compared to
dasatinib.
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Table 1.
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Table 1. Summary of inhibitor potency and selectivity. Selected compounds were
evaluated against each of the enzymes in our panel. Potency was measured via IC50 in
standard P32 kinase assay with appropriate substrate. Selectivity is represented as
the ratio of IC50 for one enzyme over another. The change in IC50, as compared to
dasatinib, is calculated and shown in the right-most columns to illustrate how
potency was effected.
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Assaying the dynamic nature of dasatinib esters
Given the profound influence of drug metabolism on inhibitor efficacy, we
characterized how our synthesis strategy may impart a unique and favorable
metabolic profile. In vivo, numerous carboxyesterases have been shown to hydrolyze
ester bonds of compounds (similar to those in the dasatinib derivatives), particularly
upon circulation to the liver. Mouse microsomal preparations contain relatively high
concentrations of carboxyesterases and frequently serve as proxies for the liver in
drug metabolism studies. In a variation of our kinase assay, select compounds were
pre-treated with these microsomal preparations prior to assaying for kinase
inhibition, alongside the untreated compound. If the derivative is a suitable substrate
for one or more carboxyesterase, the products of the subsequent reaction should
include the core dasatinib molecule. The assays relied upon the careful consideration
of proper compound concentration and a significant difference in potency between
the derivative and dasatinib. Executed properly, the microsomal esterase activity
toward the compound in question can be monitored as a function of kinase
inhibition.
As the dasatinib derivatives vary substantially in size and chemical properties,
it is worth noting that stability of the derivative likely fluctuates between
compounds, according to variations in substrate specificities of carboxyesterases.
With this dynamic in mind, we chose representative compounds for the assays,
namely 13 (-C) and 17 (-C8). From the results, summarized in Figure 4, it appears that
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compound 13 (-C) is remarkably unaffected by carboxyesterases, even after 4 hours
pre-treatment. The stability of this compound is in sharp contrast to that of 17 (-C8),
which showed significant changes in inhibition after just 20 minutes pre-treatment.
After two hours, compound 17 (-C8) inhibited nearly all kinase activity. This
observation is consistent with adduct hydrolysis by microsomal carboxyesterase and
recovery of the dasatinib core molecule (which is more than six times as potent). The
dynamic offered by these esterified derivatives can be quite advantageously applied
toward engineering a unique drug metabolic profile.
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Figure 4.
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Figure 4. Microsomal preparations metabolize dasatinib derivatives. Treatment of
compounds with mouse microsomal preparations prior to inhibition assays
demonstrate the differential metabolism of compounds, likely due to desterification
via carboxyesterases. The time course was done with compounds -C and -C8 at
800nM against Abl to highlight the differences. At this concentration, each compound
is expected to have little to no inhibition of Abl as a result of the adduct used at the
derivatized position of dasatinib. After 2 hours of treatment, compound -C8, but not C, recovers almost all of its potency, relative to the core compound.
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Development of a fluorescent dasatinib derivative
To expand upon the vast potential offered by dasatinib derivatives, we sought
to construct a fluorescent probe for in vitro characterization of kinases. Tethered to
dasatinib by a glycine linker, a fluorescein conjugated derivative was synthesized
(compound 26). The compound was assayed against Src, finding an IC50 of 1nM. The
affinity of the dasatinib-fluorescein compound was then measured using a
fluorescence polarization binding assay.
In such an assay, polarized light of a specific wavelength is used to excite the
fluorescein molecule, which in turn emits light at a higher wavelength. The degree to
which the emitted light is depolarized depends on the free rotation of fluorescein,
which is inversely correlated with ligand binding. Thus, the binding affinity of a
fluorescein-ligand conjugate for a given receptor can be measured by recording the
polarization of light in serial dilution of the receptor and fitting the data to a standard
ligand binding curve.
We sought to measure the affinity of our ligand for a form of Src that is
deficient in kinase activity (kdSrc). This mutant kinase is often able to be purified to
significantly higher concentrations than active kinase, which adds to the convenience
of the assay and broadens its potential application (as discussed later). The binding
curve generated from these assays (shown in Figure 5A) reveals an affinity of 15nM
toward kdSrc by our fluorescein-dasatinib conjugate (compound 26). This value was
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higher than expected and may reflect differences between active/inactive kinase
forms or limitations of the assay’s lowest detection limit.
To explore the utility of this fluorescent probe, we employed a variation of
this assay to determine the binding affinity of unlabeled dasatinib via a competitive
binding assay. In this assay, fixed concentrations of the fluorescent probe and kinase
were used to produce a high polarization signal. The reactions were then titrated
with unlabeled dasatinib while recording polarization. The resulting data was
graphed and curve fitting analysis provided a binding constant of 3nM for dasatinib
(Figure 5B).
The results of these fluorescence polarization binding assays with kinase
deficient substrate are fairly consistent with the IC50’s derived from the radio-ligand
kinase assays. The difference between the measured affinities of the fluorescent
probe and dasatinib accurately predict the relative potency of the compounds as
kinase inhibitors. Combined with the ease of polarization binding assays, the utility
of compound 26 (-G-Flu) as a probe for inhibitor development is clear.
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Figure 5.
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Figure 5. Polarization binding assays using a fluorescent dasatinib derivative.(A)
Fluorescence polarization assay of the kinase deficient Src catalytic domain titrated
against compound -G-Flu (400nM). A Kd of 15nM was determined for the ligand. (B)
Competitive binding assay of compound -G-Flu (50nM) and dasatinib against the
kinase deficient Src catalytic domain (125nM) reveals a Kd of 3nM, as measured via
fluorescence polarization (50mM HEPES, pH 8.0).
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Discussion and Conclusions
Library construction
Based upon the wealth of available structural data and past successes of
dasatinib modifications for affinity-based interaction studies, we hypothesized that
the exceptional potency of dasatinib would support its use as a molecular scaffold for
the synthesis of novel kinase inhibitors with enhanced specificity. The solved crystal
structures of dasatinib in complex with several PTK catalytic domains demonstrate
the common manner in which the inhibitor binds PTK active sites. Particularly
intriguing to us, is a hydroxyl group of dasatinib that extrudes from the binding
pocket to the surface of the kinase. In literature, there are numerous examples of
dasatinib (and other kinase inhibitors, as well) that have been modified at this
position through the coupling of compounds to agarose resin or other molecules.
These modifications enabled efficient extraction of PTKs that are potential dasatinib
targets from various cancer cells and tissues. These affinity-driven applications rely
upon specific interaction or recognition of kinases, which suggests that the inhibitor
portions of these compounds retain, at least in part, their ability to bind PTK active
sites. We reasoned that if large resin attachment does not abolish the affinity of
dasatinib, then smaller chemical adducts should be well tolerated, too.
In the present study, we sought to take advantage of this feature of dasatinib
by attaching a series of small molecules in an effort to impart novel inhibitor
characteristics. In the spirit of rapid library development, we desired a synthesis
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strategy that was efficient, convenient, and easily employed to obtain derivatives
with a wide range of chemical properties. To meet these criteria, we opted for batch
synthesis directly from dasatinib (free base) by esterification of its hydroxyl group to
carboxylic acid containing compounds.
A potential drawback to any derivitization, of course, is the potential
destruction of key features of the original molecule. During initial development of
dasatinib by Bristol-Meyers-Squibb, the hydroxyl group was determined to be
necessary for proper activity of the inhibitor (personal communication with R. Tiwari,
addition citation?). Upon review of the crystallized ligand, it seems likely that the
proper binding orientation of the core molecule is stabilized by energetically favoring
exclusion of the alcohol from the binding pocket. Docking studies of this molecule
without the hydroxyl group support this idea, as calculated binding energies rise and
predicted conformation deviates substantially from the known crystal structures.
Additionally, this polar group’s inclusion probably enhances the solubility or
bioavailability of hydrophobic dasatinib core molecule. Thus, our derivitization of
dasatinib, which targets this position for modification, threatens to disturb proper
binding conformation and solubility-related characteristics. The potency with which
the derivatives inhibit the PTKs in our panel suggests proper orientation is likely
achieved by most, if not all compounds.
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Derivitization alters kinase selectivity
The structural diversity of target kinases is a central element to this study, as
we endeavor to identify the different types of inhibitor interactions that confer
specificity. For this reason, we chose three kinases that represent divergent nonreceptor PTK families, distinct in structure and function. An ideal inhibitor would
target just one of these kinases through recognition of one or more of its distinct
structural features, not found in more distantly related PTKs. Therefore, our diverse
panel of kinases serves to increase our chances of identifying novel compounds that
more closely resemble an ideal inhibitor.
With that idea in mind, it is important to recognize that our kinase inhibitor
scaffold, dasatinib, already has a built in bias toward certain kinases, particularly the
Abl and Src families, as compared to others, like Csk. This suggests two things: first,
that dasatinib recognizes structural elements common to all three kinases, and
second, that Csk possesses features that limit this interaction. It is, therefore,
reasonable to assume that complete reversal in this pattern of specificity is unlikely
to occur without a major change in binding mode. The inhibitor would not only have
to overcome its previously limited interaction with Csk, but also would have to
develop some new interaction that is not tolerated by Abl and Src. Therefore, when
starting from a biased inhibitor, altered selectivity is probably most likely to occur as
a result of either the elimination or exaggeration of an inherent bias.
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From this line of reasoning, it makes sense that our library of derivatives
displays no signs of dramatic reversals in kinase selectivity pattern. All of the
compounds investigated better inhibit Src than Abl, and Abl was always inhibited
more than Csk. This apparent limitation aside, our measures of selectivity do change
dramatically for a number of inhibitors, simply by enhancing a pre-existing bias of
dasatinib for or against a given kinase. In one of the most dramatic examples, the IC50
of compound 15 (-E) increased only mildly for Src (+16%) but greatly for Csk (+186%)
and even more so for Abl (+486%). While other compounds such as 13 (-C) and 18 (C10) also possessed significantly altered kinase selectivity, compound 15 (-E) was

particularly unique for its minimal loss of potency toward Src.
The changes in kinase inhibitor specificity are quite remarkable considering
the limited size of the library generated. Compound 15 (-E) demonstrates the ease
with which dasatinib derivatives can be developed to significantly alter kinase
selectivity. An IC50 for Src that is more than a magnitude lower than for other kinases
is certainly quite notable and, we believe, represents a major step in the
development of truly specific PTK inhibitors. Furthermore, this success can be built
upon by expanding this strategy to include many new dasatinib derivatives for study
and comparison to compound 15 (-E).
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Structural basis of increased selectivity
The structural variation of PTKs outside the ATP binding pocket is localized to
a few small areas. One such region is located at the end of α-helix D of the peptide
binding lobe and extends to α-helix E. Even among closely related PTKs, like the Src
Family Kinases, a great deal of structural variation exists here. This region has also
been implicated as a key site of substrate recognition in some kinases.20
Furthermore, α-helix D is in very close proximity (within a few angstroms) to the
hydroxyl group of dasatinib.
One hurdle to developing dasatinib derivatives in this manner has to do with
the size of the compounds being tethered to the inhibitor. If these are too short or
too long, they will likely miss the targeted α-helix D. Likewise, bulkier compounds
threaten to interfere via steric hindrance. One means by which we sought to alleviate
such concerns was to simulate the binding of potential compounds using molecular
modeling software. Retrospective analysis of these models, in conjunction with our
biochemical data and the available crystal structures of Abl, Csk, and Src, offer
valuable insight into the changes in specificity we observed from our compounds.
The first and, perhaps, most exciting feature that the models predict is the
preferred orientation of the compounds that were attached to dasatinib. Despite
allowance to rotate freely, almost all of the simulated dockings favor interaction with
the region surrounding α-helix D, rather than the equally proximal ATP binding lobe
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of the kinase. Undoubtedly, this orientation better positions the inhibitor for possible
contact with structural features that are unique to any given kinase.
For example, two of the three most common hydrogen bonds, uniquely
formed by dasatinib derivatives, which we observed in the dockings, occur with sidechain residues of Lyn’s α-helix D (S333 and E335). The corresponding sites of Src
(G352 and M354) and Csk (S280 and R282) would clearly produce different results,
while Abl deviates in structure so greatly at this position; it is hard to identify
cognates. While it is difficult to make any specific claims from molecular docking
simulations, it seems rather impossible to identify structural features other than αhelix D that could explain the level of differentiation that we observed, by the kinases
we examined.
Key features of α-helix D may also explain the altered selectivity we observed
of the fatty acid conjugated derivatives. The extreme effects that these molecules
have on potency are likely due to exclusionary interactions with the polar surface of
the kinase that surrounds the exit from the inhibitor binding pocket. This can easily
be seen by coloring the surfaces of the kinases according to hydrophobicity. In Src,
however, the pattern of hydrophobicity at the end region of α-helix D is such that a
clear pathway to α-helix E (also fairly hydrophobic) is maintained. This may explain
the longer-chained fatty acid derivatives’ enhanced capacity to inhibit Src, relative to
the other kinases.
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The structural evidence examined thus far suggests that α-helix D offers the
greatest potential avenue of interaction with the synthesized compounds. The novel
specificities of the dasatinib derivatives we generated certainly imply unique
interactions have been formed with the PTKs they inhibit. While more conclusive
evidence remains to be collected, it appears highly likely that the modulation of
kinase-specific inhibition observed in this study is a direct result of novel interactions
outside the ATP binding pocket, particularly α-helix D.

Implications in drug metabolism
The ADME characteristics of a given kinase inhibitor are vital to its usefulness
as a therapeutic tool. How well the drug gets taken into the target cells and how long
it remains in active form are direct functions of the chemical properties inherent in
the molecule. Particularly, susceptibility of a drug to the hosts’ metabolic processes is
a major part of this. The stability assays performed in this study highlight an
important feature of our dasatinib derivatives.
Consider the compound 17 (-C8), which displays a low nanomolar IC50 that is
over an order of magnitude greater than dasatinib. While this study does not address
bioavailability, we have observed that the compound is readily metabolized to a
highly active inhibitor by carboxyesterases from the liver. Therefore, if titrated
properly, this compound may offer considerable value as a pro-drug for the extended
release of dasatinib.
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The utility of other derivatives, perhaps not metabolized by carboxyesterases,
also opens the door for new applications. Compound 13 (-C) for example, is another
low nanomolar inhibitor that actually displays enhanced specificity for Src compared
to dasatinib. While overall potency is diminished to some degree, the added
specificity may provide the proper trade-offs to enable more effective outcomes.
Perhaps the most interesting feature of this compound, however, is its inability to be
broken down by the microsomal preparations. The fact that the Cys adduct appears
to disrupt the inhibitor’s metabolic break-down offers evidence that this strategy
may be employed to subvert other enzymatic components of a host’s drug
metabolism, to effectively increase half-life of the compound.
The broad applications offered by an altered drug metabolic profile are
numerous and multifaceted. Any derivative, no matter how small the alteration, can
potentiate major changes. The huge chemical diversity that is possible with the
strategy we describe here, however, can be rapidly and conveniently applied to
screen for desired characteristics, without resynthesizing the core dasatinib
molecule. With these ideas in mind, further investigation of the unique ADME
features of these compounds and newly synthesized dasatinib derivatives seems
merited, given the potential therapeutic benefits of increased stability and extended
release.
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Fluorogenic dasatinib derivatives
Compound 26 (-G-Flu) is a dual-purpose inhibitor with broad potential
applications. As an inhibitor, it can bind to a kinase tightly, while enabling its visible
detection. This may be particularly useful as a molecular diagnostic tool for imaging.
Likewise, in vitro techniques may find this compound useful in FACS for monitoring
kinase expression. Since this compound is capable of measuring the binding of
unlabeled inhibitor, it will be especially adaptable to high-throughput kinase inhibitor
drug discovery.
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Methods
Reagents and chemicals
[γ-32P]-ATP (6,000 Ci mol−1) was purchased from PerkinElmer for kinase assays
and pre-cast protein gels were bought from BioRad. Dasatinib was obtained as free
base from LC Laboratories. All reagents used for bacterial culture and protein
expression were purchased from Fisher. All other chemicals reagents were obtained
from Sigma.

Molecular Modeling
Crystal structure 2ZVA of protein-tyrosine kinase Lyn in complex with
dasatinib (ligand identifier: 1N1) was downloaded from the PDB (www.pdb.org) and
edited within AutoDockTools in preparation for simulations, according to the
guidelines provided. In order to accurately reproduce the crystal structure in control
dockings, the receptor was held rigid and the rotatable bonds (torsions) of the core
dasatinib structure were frozen with the exception of the C13-N5 and N6-C20 bonds.
Based on the superimposition of other solved structures, these appear to be the only
bonds to display any great deviation from kinase-to-kinase. The virtual ligands were
prepared using Discovery Studio (Dockings were performed with an exhaustiveness
of 256 within a search space measuring 22x24x28, centered at (11, 90.5, 57.5) x,y,z.
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Synthesis of Dasatinib Derivatives
Synthesis and purification of all dasatinib derivatives was carried out by the
lab of Dr. Keykavous Parang, according to standard protocols.

Protein Expression and Purification
Enzymes and protein substrate were prepared as previously described.21,

22

Briefly, vectors for expressing Abl, CrkL, or Csk as GST-fusions and the 6xHis-tagged
Src catalytic domain (SrcCata) were made and cloned into appropriate E. coli.
systems. For each, 1-liter LB cultures were grown at 37°C until an OD600 of about 1
was

reached

and

then

induced

at

RT

with

0.4

mM

isopropyl

β-d-

thiogalactopyranoside while shaking at 250 rpm for 4-6 hours. Cells were harvested
at 4°C via centrifugation at 7,000 x g. Pellets were either stored at -20°C or
immediately re-suspended in appropriate lysis buffer: PBS + β-mercaptoethanol, pH
7.3 for GST-fusions and 50mM HEPES + 200mM NaCl + 10mM imidazole + 0.01%
triton x-100, pH 8.0 for 6xHis-proteins. Following 4x15sec sonication in 12mL glass
tubes on ice, lysates were cleared by centrifuge for 10min at 22,000 x g and
incubated with 1mL agarose resin at 4°C for 1hr. This suspension was then loaded
into a column, washed with lysis buffer and eluted with either 50mM Tris + 10mM
GSH, for GST-fusions, or 50mM HEPES + 200mM imidazole to release 6xHis-tagged
protein. All samples were quantified using standard Bradford assays and analyzed by
SDS-PAGE/coomassie staining to check purity.
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Kinase Assays and IC50 Measurements
Enzyme activity and inhibition was characterized using the following methods,
adapted from previous work.21, 22 Csk and SrcCata activity levels were measured from
incubations with polyE4Y (1mg/mL) and CrkL (0.5mg/mL) was used as a substrate for
Abl. Dasatinib and derivatives were dissolved in 10% DMSO / 90% kinase buffer
solution (KB10) and diluted in series as needed. In screening assay reactions, multiple
inhibitors were used at a fixed concentration for relative inhibition comparisons. IC50
measurement assays, however, had a single inhibitor but each reaction varied in the
compound’s concentration. In assays requiring pre-treatment, undiluted stocks of the
inhibitors were incubated at RT with microsomal preparations to a final
concentration of 12.5ug/mL.
In each assay, a series of 50µL duplicate reactions were setup at 30°C to
contain the appropriate inhibitor concentration, substrate, and enzyme in 75mM
EPPS, pH 8.0 + 200μM [γ-32P]-ATP (~1000 dpm/pmol) + 12 mM MgCl2 + 5% glycerol +
0.005% Triton X-100. The reactions were stopped after 20min incubation by blotting
onto filter paper strips prior to precipitation and washing in hot 5% trichloroacetic
acid. The strips were then sorted and separated into vials of scintillation fluid for
signal quantification in a Beckman Coulter LS-6500. From these counts, enzyme
turnover was calculated for each reaction.
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Binding assays
To determine the binding of compound 26 (-G-Flu) toward the kinasedeficient Src catalytic domain (kdSrcCata), fluorescence polarization (FP) binding
assays were carried out as described previously.23, 24 Specifically, a series of kdSrcCata
dilutions were made, ranging from 62.5 – 1,000nM (and an additional balnk). Each
dilution contained 400nM compound 26 (-G-Flu) in 50mM Tris, pH 8.0. FP was then
detected using a PerkinElmer LS55 Luminescence Spectrophotometer at 25°C.
Wavelengths utilized were 485 nM for excitation and 530 nM for emission. The net
change in FP was plotted as a function of kdSrcCata concentration and fit to the
following equation: FP = FPmax x [kdSrcCata] / (KD + [kdSrcCata]). Where FPmax is
the maximum polarization value at saturation and KD is the dissociation constant of
compound 26 (-G-Flu) binding to kdSrcCata. Regression analysis was carried out in
LabFit software (www.labfit.net).
To determine the binding of unlabeled dasatinib, its ability to compete against
the fluorogenic compound for binding to kdSrcCata was determined by an FP
competition binding assay.23 This assay setup differs from the above in that each
tube had a 50nM concentration of compound 26 (-G-Flu), 125nM kdSrcCata (held
constant), and concentrations of the unlabeled dasatinib from 200 – 1,600nM. The
competing ligand’s KD was then determined by plotting the FP as a function of the
increasing concentration of the unlabeled compound and fitting the curve to the
equation: FP = A x ([kdSrcCata]t x [Probe]t x KD2)/( KD1 x KD2 + KD1 x [Competitor]t +
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[kdSrcCata]t x KD2), where KD1 is the dissociation constant of compound 26 (-G-Flu), as
determined above, and KD2 is the dissociation constant of the unlabeled dasatinib. A
is a conversion factor between the concentration of the probe-kinase complex and
the FP value. [kdSrcCata]t and [Probe]t were total kinase and compound 26 (-G-Flu)
concentrations. [Competitor]t is the total concentration of unlabeled, competing
ligand.
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